Document:

Exhibit 10.9

 

NEW EXCLUSIVE LICENSE AGREEMENT

 

NEW EXCLUSIVE LICENSE
AGREEMENT, dated May 14, 2015 (the “Effective Date”), between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW
YORK (“Columbia”), and TransTech Pharma, LLC (“Company”).

 

WHEREAS Columbia and
a predecessor-in-interest of the Company, TransTech Pharma, Inc., previously entered into an Amended and Restated Exclusive License
Agreement on October 1, 2003, as further amended on December 22, 2003, June 30, 2006, September 11, 2006, and August 12, 2010 (the
“Amended 2003 Agreement”); and

 

WHEREAS
Columbia and TransTech Pharma, Inc. terminated the Amended 2003 Agreement on or about February 3, 2012; and

 

WHEREAS, the parties
desire to enter into this New Exclusive License Agreement in the manner provided for herein;

 

NOW THEREFORE, in consideration
of the mutual promises contained herein and for other good and valuable consideration the parties hereto agree as follows:

 

1.             Definitions.

 

a.                  
“Agreement” shall mean this New Exclusive License Agreement between the parties.

 

b.                 
“Affiliate” shall mean any corporation or other business entity that directly or indirectly controls, is controlled
by, or is under common control with the Company. Control means ownership or other beneficial interest in 50% or more of the voting
stock or other voting interest of a corporation or other business entity.

 

c.                  
“Licensed Patent” shall mean United States Patent No. 6,677,299.

 

d.                 
“Licensed Product” shall mean any RAGE-inhibiting small molecule, including but not limited to the molecule
designated by the Company as TTP488, (i) the discovery, development, manufacture, use, sale, rental, lease, importation, and offer
to sell of which is covered by a Claim of the Licensed Patent or (ii) that has been discovered or developed through the use of
or that uses Licensed Research Information or Licensed Materials.

 

e.                  
“Licensed Research Information” shall have the meaning as set forth in the Amended 2003 Agreement.

 

f.                  
“Licensed Material” shall have the meaning as set forth in the Amended 2003 Agreement.

 

 

* Confidential treatment has been requested
with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted
and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

g.                 
“Net Sales” shall mean the total of all revenues and other value received by the Company and any Affiliate or
Sublicensee for the manufacture, use, sale, rental, or lease of Licensed Products, less returns and customary trade discounts actually
taken, outbound freight, value-added, sales or use taxes, custom duties, bad debts actually taken in accordance with current United
States generally accepted accounting principles and not factored to third parties, refunds, customary chargebacks and any other
allowances actually paid, granted or accrued that effectively reduce the net selling price, rebates actually paid, granted or accrued
to any governmental authority (or branch thereof), or to any third party payor, third party administrator, or third party contractee
responsible for healthcare insurance covering Licensed Products, discounts mandated by, or granted to meet the requirements of,
applicable law, including legally required chargebacks and retroactive price reductions, and adjustments arising from consumer
discount programs or similar programs provided to low-income, uninsured or other patients. In the case of transfers of Licensed
Products to an Affiliate by the Company for sale, rental, or lease of such Licensed Products to third parties by such Affiliate,
Net Sales shall be based upon the greater of the total fees and other consideration charged by the Affiliate to third parties or
the total fees and consideration charged by the Company to the Affiliate. If Licensed Products are sold as only a part of a services
package in regard to an unlicensed combination which includes a charge for Licensed Products, then the Net Sales of the Licensed
Products shall be that portion of the entire combination which is fairly attributable to the Licensed Products component thereof,
or as separately shown on an invoice.

 

h.                 
“Claim” shall mean a claim of the Licensed Patent, which claim has not lapsed, been disclaimed or become abandoned
and which claim has not been declared invalid or unenforceable by a court of competent jurisdiction in a decision from which no
appeal has or can be taken.

 

i.                   
“RAGE” shall mean the receptor for advanced glycation endproducts which is a membrane protein that is a member
of the immunoglobulin supergene family, and a receptor for multiple ligands, including advanced glycation endproducts, amyloid
beta, S100B, and high mobility group box 1 protein.

 

j.                   
“Sublicensee” shall mean any unaffiliated third party to whom the Company has granted a sublicense pursuant
to this Agreement.

 

2.             License Grant.

 

a.                  
Columbia grants to the Company and its Affiliates, upon and subject to all the terms and conditions of this Agreement:

 

(i)                
a worldwide exclusive license under the Licensed Patent to discover, develop, manufacture, use, sell, have sold, import,
have made, offer to sell, rent, or lease Licensed Products;

 

(ii)              
a worldwide license to use any Licensed Research Information to discover, develop, manufacture, use, sell, have sold, import,
have made, offer to sell, rent, or lease Licensed Products, which license shall be exclusive until such time as the Licensed Research
Information is published or otherwise publicly distributed and non-exclusive thereafter; and

 

    	2

    	 

    

(iii)            
a worldwide exclusive license to use any Licensed Materials to discover, develop, manufacture, use, sell, have sold, import,
have made, offer to sell, rent, or lease Licensed Products.

 

b.                 
Columbia grants to the Company the right to grant sublicenses under the Licensed Patent to third parties, provided that
(i) the Sublicensee agrees to abide by all the terms and provisions of this Agreement; (ii) the Company remains fully liable for
the performance of its and its Sublicensee’s obligations hereunder; and (iii) the Company notifies Columbia of any grant
of a sublicense and provides to Columbia, within 30 days after each sublicense is executed, a copy of any sublicense agreement;
provided, however, that if Company plans to grant a sublicense to a Sublicensee outside the United States, Europe or Japan, Company
shall first obtain Columbia’s approval of any proposed sublicense prior to execution thereof, which approval Columbia shall
not unreasonably withhold.

 

c.                  
All rights granted by Columbia to the Company under this Agreement are subject to the requirements of 35 U.S.C. Sections
200 et seq., as amended, and its implementing regulations and policies.

 

d.                 
Columbia unconditionally agrees, promises, and covenants, fully and forever, for itself and any Affiliate, predecessors,
successors, and heirs and assigns, that it will not sue, assert any claim, counterclaim, demand, action, cause of action, or lien
against, or otherwise enforce, in law or in equity, the Licensed Patents as defined in the Amended 2003 Agreement, any patent issuing
from any application that falls within the definition of Licensed Patents in the Amended 2003 Agreement, or any patent that issues
directly or indirectly from PCT/US2014/016137 against Company (including its Affiliates, Sublicensees, predecessors, successors,
or heirs and assigns) or Company’s customers, suppliers, importers, manufacturers, distributors, or insurers, in connection
with the manufacture, use, offer for sale, sale, or importation of Licensed Products, nor will it cause or authorize any person
or entity to do any of the foregoing.

 

3.             Royalties and Payment.

 

a.                  
Unless the Agreement has been terminated or expired pursuant to Section 16, in consideration of the licenses granted under
Section 2(a) of this Agreement, the Company shall pay to Columbia the following payments and royalties only:

 

(i)                
$750,000 upon the earlier to occur of (A) approval by the United States Food and Drug Administration or its foreign equivalent
in any European Union member country, Australia, Canada or Japan to market the first Licensed Product of the Company, an Affiliate,
or a Sublicensee, and (B) sale or transfer of the portion of Company’s business related to the subject matter of this Agreement,
unless such sale or transfer is to an Affiliate or to a third party having annual gross revenues of greater than $500 million;

 

(ii)              
A royalty of [***] of Net Sales of Licensed Products by the Company, an Affiliate, or any Sublicensee during the term of
United States Patent No. 6,677,299 (“the ‘299 patent”); and

 

    	3

    	 

    

(iii)            
$100,000 annual fee payable on December 15th of each year from 2015 through and including 2021, for a total of
seven such payments, provided that Columbia sends Company an invoice for each such annual payment at least 30 days in advance of
the due date of each such payment.

 

Columbia may, in its
sole discretion, apply any portion of the fees paid under Section 3(a)(i) and Section 3(a)(iii) towards patent expenses incurred
by Columbia relating to the Licensed Patents as defined in the Amended 2003 Agreement not already reimbursed by Company prior to
the execution of this Agreement or in accordance with Section 6a.

 

Nothing herein shall obligate the Company
to remit to Columbia any portion of any payment or other thing of value received from a Sublicensee other than royalties on Net
Sales by Sublicensees as provided for herein.

 

4.             Reports and Payments.

 

a.                  
Beginning on the date of first sale, rental or lease of Licensed Products, or before the last business day of January, April,
July, and October of each year in which the Company owes royalties in accordance with section 3(a)(ii), the Company shall submit
to Columbia a written report with respect to the preceding calendar quarter (the “Payment Report”) stating separately:

 

(i)                
Net Sales received by the Company and any Affiliate during such quarter;

 

(ii)              
In the case of transfers of Licensed Products to an Affiliate by the Company for sale, rental, or lease of such Licensed
Products by the Affiliate to third parties, Net Sales by the Company to the Affiliate and Net Sales by the Affiliate to third parties
during such quarter;

 

(iii)            
Amounts accruing to, and received by, the Company from its Sublicensees during such quarter;

 

(iv)            
Net Sales by Sublicensees during such quarter; and

 

(v)              
A calculation of the amounts due to Columbia under section 3.

 

b.                 
Simultaneously with the submission of each Payment Report, the Company shall make payments to Columbia of the amounts due
for the calendar quarter covered by the Payment Report. Columbia shall be entitled to receive payment of the royalty set forth
in Section 3(a)(ii) hereof on Net Sales of a Sublicensee no less frequently than the quarter following the quarter in which such
sales are made, regardless of any provision of a Sublicense that may defer, credit or otherwise reduce or eliminate royalties payable
to the Company or an Affiliate, provided that so long as a Sublicense provides for the payment of royalties to the Company or an
Affiliate no less frequently than the quarter following the quarter in which Net Sales are made, no payment shall be due to Columbia
that is based upon Net Sales of such Sublicensee until the date the Company or its Affiliate receives its royalty payment from
such Sublicensee.

 

    	4

    	 

    

c.                  
The Company shall maintain at its principal office usual books of account and records showing its actions under this Agreement.
Upon reasonable notice, such books and records shall be open to inspection and copying, during usual business hours, by an independent
certified public accountant to whom the Company has no reasonable objection, for two years after the calendar quarter to which
they pertain, for purposes of verifying the accuracy of the amounts paid by the Company under this Agreement.

 

d.                 
Columbia agrees that all information contained in the Payment Reports rendered by Company pursuant to this Section or obtained
pursuant to the provisions herein shall be maintained in confidence by the accountant and/or Columbia. The accountant shall not
disclose to Columbia or any other party any information relating to the business of Company, except to the extent that such information
is reasonably necessary to inform Columbia of: (i) the accuracy or inaccuracy of Company’s reports and payments; (ii) compliance
or noncompliance by Company with the terms and conditions of this Agreement; and (iii) the extent of any inaccuracy or noncompliance.
Columbia shall not disclose to any third party any information that the Company has designated in writing as confidential relating
to the business of Company provided to Columbia pursuant to this Section, except as required by any applicable law or regulation.

 

5.             Reservation of Rights for Research Purposes.

 

Columbia reserves the
right to use the Licensed Patent, Licensed Research Information and Licensed Materials for noncommercial research purposes and
to permit other entities or individuals to use such Licensed Patent, Licensed Research Information or Licensed Materials for noncommercial
research purposes. Columbia shall obtain from all such entities or individuals an agreement in writing not to use the Licensed
Patent, Licensed Research Information or Licensed Materials for commercial purposes and shall inform the Company of the identity
of all such entities and individuals in advance of such transfer. Each entity or individual shall be required to execute an appropriate
confidentiality or material transfer agreement.

 

6.             Patent Prosecution and Maintenance.

 

a.                  
Columbia, by counsel it selects to whom the Company has no reasonable objection, in consultation with counsel appointed
by the Company, will prepare, file, prosecute and maintain the Licensed Patent in Columbia’s name and in countries designated
by the Company. The Company will reimburse Columbia for reasonable expenses it has incurred prior to the Effective Date of this
Agreement not previously reimbursed by Company or its predecessor in interest for filing, prosecution and maintenance of the ‘299
patent, not to exceed $45,000, provided that Columbia provides Company with an invoice describing the basis for any such expenses,
including supporting documentation upon request of the Company. Company will pay reasonable expenses incurred in the future during
the term of this Agreement in filing, prosecuting and maintaining the ‘299 patent, including attorneys’ fees, the costs
of any interference proceedings, reexaminations, or any other ex parte or inter parties administrative
proceeding before patent offices, taxes, annuities, issue fees, working fees, maintenance fees and renewal charges. Company will
not reimburse Columbia for the costs incurred by Columbia in the use of its own resources, such as employee time, and shall not
extend to patenting fees and costs incurred by Columbia after termination of this Agreement.

 

    	5

    	 

    

b.                 
Company shall solely at its own cost file and prosecute all U.S. and foreign patent applications for, and shall be the sole
owner of and maintain, all patents to the extent the inventions claimed the patents are invented or developed solely by Company.

 

7.             Infringement.

 

a.                  
Columbia will protect its Licensed Patent from infringement and prosecute infringers at its own expense when in its sole
judgment such action may be reasonably necessary, proper, and justified.

 

b.                 
If the Company shall have supplied Columbia with written evidence demonstrating to Columbia’s satisfaction prima
facie infringement of a claim of a Licensed Patent by a third party selling products in competition with the Company or
any of its Affiliates or Sublicensees, the Company may by notice request that Columbia take steps to assert the Licensed Patent.
Unless Columbia shall within three months of the receipt of such notice either (i) cause such infringement to terminate, or (ii)
initiate legal proceedings against the infringer, the Company may, upon notice to Columbia, initiate legal proceedings against
the infringer at the Company s expense. In such event the Company may deduct from payments due hereunder to Columbia reasonable
costs and legal fees incurred to conduct such proceedings, but in no event shall any payment due in any calendar quarter be reduced
by more than [***] of the amount otherwise due to Columbia hereunder. Any recovery by the Company in such proceedings shall first
be used to reimburse the Company for its reasonable costs and legal fees incurred to conduct such proceedings and next to pay to
Columbia an amount equal to all amounts withheld from Columbia by the Company under this Section 7 during the pendency of the proceedings.
The balance shall be divided [***] to the Company and [***] to Columbia.

 

If Columbia initiates
the legal proceedings against the infringer at Columbia’s expense, any recovery by Columbia in such proceedings shall first
be used to reimburse Columbia for its reasonable costs and legal fees incurred to conduct such proceedings. The balance shall be
divided [***] to Columbia and [***] to Company.

 

c.                  
In the event one party shall initiate or carry on legal proceedings to enforce a Licensed Patent against an alleged infringer,
the other party shall use its best efforts to cooperate fully with and shall supply all assistance reasonably requested by the
party initiating or carrying on such proceedings. The party that institutes any proceeding to protect or enforce a Licensed Patent
shall have sole control of that proceeding and shall be responsible for the reasonable expenses incurred by said other party in
providing such assistance and cooperation as is requested pursuant to this paragraph.

 

d.                 
Each party, within thirty (30) days of learning of any alleged infringement of Licensed Patent by a third party, shall inform
the other party, and provide any available evidence thereof.

 

    	6

    	 

    

e.                  
Neither Company nor Columbia is obligated under this Agreement to institute a suit against an alleged infringer of Licensed
Patent.

 

8.             Validity.

 

a.                  
If a prima facie case challenging the validity or enforceability of any of the Licensed Patent solely owned by Columbia
is brought against Company, Company shall promptly notify Columbia. Columbia, at its option, shall have the right, within sixty
(60) days after notification by Company of such action, to intervene and take over the sole defense of the claim at Columbia’s
sole expense.

 

9.             Warranty.

 

a.                  
Nothing in this Agreement shall be construed as a warranty or representation by either party as to the validity of any Licensed
Patent. Nothing in this Agreement shall be construed as a warranty or representation by either party that anything developed, manufactured,
used, sold, rented, leased, or otherwise disposed of under any license granted under this Agreement is or will be free from infringement
of domestic or foreign patents of other parties.

 

b.                 
Columbia represents and warrants that it has a right to grant the license in and to the Licensed Patent and Licensed Research
Information and to disclose the Licensed Research Information and to transfer the Licensed Materials set forth in this Agreement.

 

c.                  
Columbia represents and warrants that, as of the Effective Date, it does not own or have any rights to any RAGE-related
patents or patent applications that name as inventors David M. Stern, Anne Marie Schmidt, Shi Du Yan, Kevan Herold, or Ira Lamster
except for the ‘299 patent, the Licensed Patents as defined in the Amended 2003 Agreement, and PCT/US2014/016137.

 

10.           Prohibition Against Use of Names.

 

a.                  
The Company will not use the name, insignia, or symbols of Columbia, its faculties or departments, or any variation or combination
thereof, or the name of any trustee, faculty member, agent, other employee, or student of Columbia for any purpose whatsoever without
Columbia’s prior written consent. However Company may inform collaborators that Licensed Patent are owned by Columbia and
exclusively licensed to Company, and may make disclosure of the existence and terms of this Agreement to the extent reasonably
required by federal and state securities laws and regulations, provided the Company, in consultation with Columbia, makes reasonable
claims for confidential treatment of commercially sensitive information contained in this Agreement.

 

b.                 
Columbia will not use the name or trademarks/service marks of Company or any variation or combination thereof or the name
of any employee, officer or director of the Company without Company’s prior written consent. However, Columbia may state
the fact that the Licensed Patent, Licensed Research Information and Licensed Materials are licensed to the Company.

 

    	7

    	 

    

c.                  
Either party may disclose the existence of this Agreement and that the Licensed Patent is owned by Columbia and exclusively
licensed to Company.

 

11.           Compliance with Governmental Obligations.

 

a.                  
Notwithstanding any provision in this Agreement, Columbia disclaims any obligation or liability arising under the license
provisions of this Agreement if the Company is charged in a governmental action for not complying with or fails to comply with
governmental regulations in the course of taking steps to bring any Licensed Product to a point of practical application. Company
acknowledges and agrees that Columbia does not comply with Good Laboratory Practices, 21 CFR Part 58, with respect to the Research
conducted under this Agreement. In any submission by the Company to the FDA that includes data from the Research, the Company will
state that the research was not intended to be performed in compliance with Good Laboratory Practices.

 

b.                 
The Company shall comply upon reasonable notice from Columbia with all governmental requests directed to either Columbia
or the Company and provide all information and assistance necessary to comply with legitimate governmental requests.

 

c.                  
The Company shall insure that any research, development, and marketing performed by the Company under this Agreement complies
with all government regulations in force and effect including, but not limited to, Federal, state, and municipal legislation.

 

12.           Indemnity and Insurance.

 

a.                  
The Company will indemnify and hold Columbia harmless against any and all actions, suits, claims, demands, prosecutions,
liabilities, costs, and expenses (including reasonable attorneys’ fees) based on or arising out of this Agreement, including,
without limitation, (i) the development, manufacture, packaging, use, sale, rental, or lease of Licensed Products, even if altered
for use for a purpose not intended, by the Company, its Affiliates, Sublicensee, and its (or their) customers, (ii) use of Licensed
Patent, Licensed Research Information or Licensed Materials by the Company, its Affiliates, its Sublicensees or its (or their)
customers and (iii) any representation made or warranty given by the Company, its Affiliates or Sublicensees with respect to Licensed
Products, Licensed Patent, Licensed Research Information or Licensed Material.

 

b.                 
The Company shall maintain, during the term of this Agreement, comprehensive general liability and umbrella insurance, including
product liability insurance, with reputable and financially secure insurance carriers acceptable to Columbia to cover the activities
of the Company, its Affiliates and its Sublicensees, for minimum limits of $2,000,000 combined single limit for bodily injury and
property damage per occurrence and in the aggregate. Such minimum amount shall be increased prior to the Company administering
its first dose of a Licensed Product in man to an amount determined by the Company, based on advice from a nationally- recognized
insurance advisor, to be adequate and customary in the industry for the level of increased risk anticipated during the policy period,
and at each succeeding policy renewal date such minimum amount shall be reviewed on the same basis and, if necessary, increased.
The minimum limits shall in any event be increased to $5,000,000 by not later than the date the Company commences its first Phase
III testing of a Licensed Product in any country. Such insurance shall include Columbia, its trustees, directors, officers, employees,
and agents as additional insureds. The Company shall furnish a certificate of insurance evidencing such coverage, with thirty days’
written notice to Columbia of cancellation or material change.

 

    	8

    	 

    

The Company’s insurance
shall be primary coverage; any insurance Columbia may purchase shall be excess and noncontributory. Such insurance shall be written
to cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement.

 

The Company shall at
all times comply with all statutory workers’ compensation and employers liability requirements covering its employees with
respect to activities performed under this Agreement.

 

13.           Marking.

 

Prior to the issuance
of patents, the Company will mark Licensed Products made, sold, or otherwise disposed of by it under the license granted in this
Agreement with the words “Patent Pending,” and following the issuance of one or more patents, with the numbers of such
patents. Any exception to these requirements shall be approved in advance by Columbia.

 

14.           Export Control Laws.

 

This Agreement is made
subject to any restrictions concerning the export and re- export of products or technical information that the United States government
may impose from time to time (“Export Laws”). To this end, the Company shall cooperate with Columbia as reasonably
necessary to permit Columbia to comply with the Export Laws. The Company hereby represents and covenants that the Company (a) is
neither a national of nor Controlled by a national of any country to which the United States prohibits the export or re-export
of goods, services, or technology; (b) is not a person specifically designated as ineligible to export from the United States or
deal in U.S.-origin goods, services or technologies; (c) will not export or re-export, directly or indirectly, any goods, services,
or technology, to any country or person (including juridical persons) to which the United States prohibits the export of goods,
technology or services, and (d) in the event that a United States government license or authorization is required for an export
or re-export of goods, services or technology (including technical information acquired from Columbia under this Agreement and/or
any products created by using such technical information or any part thereof), the Company shall obtain any necessary United States
government license or other authorization prior to undertaking the export or re-export.

 

15.           Breach and Cure.

 

a.                  
In addition to applicable legal standards, the Company shall be considered to be in material breach of this Agreement for
(i) failure to pay fully and promptly amounts due pursuant to Section 3 and payable pursuant to Section 4; (ii) failure to comply
with governmental requests directed to Columbia or the Company pursuant to Section 11(b); or (iii) otherwise being in material
breach of this Agreement.

 

    	9

    	 

    

b.                 
Either party shall have the right to cure its material breach. The cure shall be effected within a reasonable period of
time but in no event later than 60 days after written notice of breach given by the non-breaching party.

 

16.           Term of Agreement.

 

a.                  
This Agreement shall commence as of the Effective Date and shall continue in full force and effect until its expiration
or termination in accordance with this Section 16.

 

b.                 
Unless terminated earlier under any provision of this Agreement, this Agreement shall expire on the date Company makes the
seventh (7th) annual fee due under Section 3(a)(iii) of this Agreement. At that time, the Company shall have a fully-paid-up,
irrevocable license to the Licensed Patent, Licensed Research Information, and Licensed Materials.

 

c.                  
This Agreement may be terminated by Columbia (i) upon thirty days’ written notice to the Company for the Company’s
material breach of the Agreement and the Company’s failure to cure such material breach, or (ii) should the Company commit
any act of bankruptcy, become insolvent, file a petition under any bankruptcy or insolvency act or have such petition filed against
it. Company shall have a right to terminate this Agreement with or without cause, upon sixty (60) days prior written notice to
Columbia; provided that, Company cannot terminate this Agreement without cause for one (1) year after the Effective Date.

 

d.                 
Upon any termination of this Agreement pursuant to Section 16(c), all sublicenses granted by the Company under this Agreement
shall be assigned to Columbia, provided that in the event Columbia terminates this Agreement pursuant to Section 16(c), Columbia
must promptly terminate any such sublicenses assigned to it to the extent it may do so under the terms of such sublicenses. In
the event that Columbia fails to terminate such a terminable sublicense, the termination of this Agreement will be null and void.

 

e.                  
The provisions under which this Agreement may be terminated shall be in addition to any and all other legal remedies which
either party may have for the enforcement of any and all terms hereof, and do not in any way limit any other legal remedy such
party may have.

 

17.           Notices.

 

Any notice required or
permitted to be given under this Agreement shall be sufficient if sent by certified mail (return receipt requested), postage pre-paid,

 

	if to Columbia, to:	Executive Director

Columbia Technology Ventures

Columbia University

80 Claremont Avenue #4F

New York, NY 10027

	 	 
	

    	10

    	 

    

	copy to:	General Counsel

Columbia University

412 Low Memorial Library

535 West 116th St., Mail Code 4308

New
York, NY 10027

	 	 
	if to the Company, to:	President & CEO

TransTech Pharma, LLC

4170 Mendenhall Oaks Parkway

High Point, N.C. 27265

	 	 
	copy to:	Vice President of Legal Affairs

TransTech Pharma, LLC

4170 Mendenhall Oaks Parkway

High Point,
N.C. 27265

 

or to such other address as a party may
specify by notice hereunder.

 

18.             
Entire Agreement: No Waiver: Assignment.

 

This Agreement constitutes
the entire agreement of the parties with respect to the subject matter hereof, and shall not be further amended except by means
of a written instrument signed by authorized representatives of the parties. No course of conduct shall constitute a waiver of
any terms or conditions of this Agreement, unless such waiver is specified in writing, and then only to the extent so specified.
A waiver of any of the terms and conditions of this Agreement on one occasion shall not constitute a waiver of the other terms
of this Agreement, or of such terms and conditions on any other occasion. This Agreement may not be assigned by either party without
the written consent of the other party, which consent shall not be unreasonably withheld or delayed; provided, however,
that the Company may assign this Agreement without the prior written consent of Columbia (i) in connection with the sale of all
or substantially all of its assets or the sale or transfer of the portion of its business related to the subject matter of this
Agreement; (ii) to the surviving entity in any merger, consolidation or reorganization of the Company; (iii) to any of its Affiliates;
or (iv) to satisfy a regulatory requirement imposed upon the Company by a governmental body with appropriate authority. This Agreement
shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns.

 

19.             
Governing Law.

 

This Agreement shall
be governed by New York Law applicable to agreements made and to be performed in New York.

 

20.             
Release.

 

Each party, on behalf
of itself, its Affiliates, and their respective directors, officers, employees, agents, representatives, assigns, predecessors,
or successors hereby releases, acquits, and forever discharges the other party including each of their respective current and future
customers, importers, manufacturers, distributors, suppliers, insurers, attorneys, representatives and agents, their successors
and assigns, from any and all pending and potential claims, demands, obligations, all manner of actions, causes of actions, suits,
debts, liabilities, losses, damages, attorneys’ fees, costs, expenses, judgments, settlements, interest, punitive damages,
and other damages or costs of whatever nature, whether known or unknown, pending or future, certain or contingent, arising out
of, derived from, predicated upon or relating to the Amended 2003 Agreement, the “Research Agreement” between Columbia
and a predecessor of Company dated May 25, 2000, expired May 25, 2005, the “Research Agreement” between Columbia and
a predecessor of Company dated June 30, 2006, effective May 25, 2005, and the “Agreement Regarding Addendum No. 1 to Exhibit
A of Research Agreement” between Columbia and a predecessor of Company, dated August 24, 2007.

 

    	11

    	 

    

IN WITNESS THEREOF, Columbia and the Company
have caused this Agreement to be executed by their duly authorized representatives as of the date first written above.

 

	 	THE TRUSTEES OF COLUMBIA UNIVERSITY

                           IN THE CITY OF NEW YORK

	 	 
	 	By	/s/ Orin Hershowitz
	 	 
	 	TT: 46712
	 	 
	 	TRANSTECH PHARMA, LLC
	 	 
	 	By	/s/ Stephen L. Holcombe

 

 

 

    	12Exhibit 10.10

 

LICENSE AND RESEARCH AGREEMENT

 

BY AND BETWEEN

 

CALITHERA BIOSCIENCES INC.

 

AND

 

HIGH POINT PHARMACEUTICALS, LLC

TRANSTECH PHARMA LLC

 

DATED AS OF MARCH 5, 2015

 

 

 

 

* Confidential treatment has been requested with respect to
portions of this agreement as indicated by “[***]” and such confidential portions have been deleted and filed separately
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

 

 

Page

 

	Article I Definitions	1
	1.1   “Acceptable Human Exposure”	1
	1.2   “Act”	1
	1.3   “Affiliate”	2
	1.4   “Bankruptcy Code”	2
	1.5   “Business Day”	2
	1.6   “Calendar Quarter”	2
	1.7   “Calendar Year”	2
	1.8   “Calithera-Derived Molecule”	2
	1.9   “Calithera Intellectual Property”	2
	1.10   “Calithera Know-How”	2
	1.11   “Calithera Patent Rights”	2
	1.12   “Clinical Candidate”	2
	1.13   “Combination Product”	3
	1.14   “Commercialization” or “Commercialize”	3
	1.15   “Commercially Reasonable Efforts”	3
	1.16   “Control” or “Controlled”	3
	1.17   “Cover”, “Covering” or “Covered”	3
	1.18   “Covered Period”	3
	1.19   “Development” or “Develop”	4
	1.20   “Development Plan”	4
	1.21   “Development Term”	4
	1.22   “EMA”	4
	1.23   “EU”	4
	1.24   “FDA”	4
	1.25   “Field”	4
	1.26   “First Commercial Sale”	4
	1.27   “FTE”	4
	1.28   “FTE Rate”	4
	1.29   “GAAP”	5
	1.30   “Generic Competition”	5
	

    	 

    	 

    

	1.31   “Generic Product”	5
	1.32   “Governmental Authority”	5
	1.33   “Hexokinase Inhibitor”	5
	1.34   “High Point Intellectual Property”	5
	1.35   “High Point Know-How”	5
	1.36   “High Point Molecule”	5
	1.37   “High Point Patent Rights”	5
	1.38   “HPP399”	6
	1.39   “IND”	6
	1.40   “IND Enabling GLP Toxicology Study”	6
	1.41   “Indication”	6
	1.42   “Initiation”	6
	1.43   “Know-How”	6
	1.44   “Law” or “Laws”	6
	1.45   “Legal Exclusivity”	6
	1.46   “Licensed Product”	7
	1.47   “Losses”	7
	1.48   “Major EU Country”	7
	1.49   “Major Markets”	7
	1.50   “Manufacture” or “Manufacturing”	7
	1.51   “Marketing Authorization”	7
	1.52   “MHLW”	7
	1.53   “NDA”	7
	1.54   “Net Sales”	8
	1.55   “Objective Response”	9
	1.56   “Party”	10
	1.57   “Patent Rights”	10
	1.58   “Person”	10
	1.59   “Phase I Clinical Trial”	10
	1.60   “Phase II Clinical Trial”	10
	1.61   “Phase III Clinical Trial”	10
	1.62   “Program Molecule”	10
	1.63   “Program Patent Rights”	10
	1.64   “Regulatory Approval”	11
	

    	ii

    	 

    

	1.65   “Regulatory Authority”	11
	1.66   “Research Plan”	11
	1.67   “Research Program”	11
	1.68   “Research Program Term”	11
	1.69   “ROW”	11
	1.70   “Small Molecule”	11
	1.71   “Sublicensee”	11
	1.72   “Territory”	11
	1.73   “Third Party”	11
	1.74   “Valid Claim”	12
	1.75   Additional Definitions	12
	Article II GRANTS OF RIGHTS	13
	2.1   High Point Grants of Rights	13
	2.2   Calithera Grants of Rights	14
	2.3   Rights Retained by the Parties	14
	2.4   Section 365(n) of the Bankruptcy Code	14
	2.5   Exclusivity	14
	Article III RESEARCH	15
	3.1   General	15
	3.2   High Point FTE Commitments	15
	3.3   Research Program Coordinators	15
	3.4   Calithera Contributions	16
	3.5   High Point Assistance	16
	Article IV DEVELOPMENT	16
	4.1   General	16
	4.2   Development Forum	16
	4.3   Exchange of Information Regarding Development	17
	Article V COMMERCIALIZATION	17
	5.1   General	17
	5.2   Commercialization Plans	18
	Article VI DILIGENCE	18
	6.1   Commercially Reasonable Efforts	18
	6.2   Specific Efforts with Respect to Program Molecules and Licensed Products	18
	6.3   Failure to Meet Diligence Obligations	18
	

    	iii

    	 

    

	Article VII FINANCIAL PROVISIONS	19
	7.1   Initial License Payment	19
	7.2   Research Program	19
	7.3   Development, Manufacturing and Commercialization Costs	19
	7.4   Event Milestone Payments	20
	7.5   Sales Milestone Payments	21
	7.6   Licensed Product Royalties	22
	7.7   Reports; Payments	23
	7.8   Books and Records; Audit Rights	23
	7.9   Taxes	24
	7.10   Payment Method and Currency Conversion	24
	7.11   Blocked Payments	24
	7.12   Late Payments	24
	Article VIII INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS	25
	8.1   Ownership of Inventions	25
	8.2   Prosecution and Maintenance of Patent Rights	26
	8.3   Third Party Infringement	28
	8.4   Patent Invalidity Claim	29
	8.5   Patent Term Extensions	29
	8.6   Patent Marking	30
	8.7   Interpretation of Patent Judgments	30
	8.8   Certification under Drug Price Competition and Patent Restoration Act	30
	8.9   Consents as to Joint Inventions and Joint Patents	31
	Article IX CONFIDENTIAL INFORMATION	31
	9.1   Treatment of Confidential Information	31
	9.2   Confidential Information	32
	9.3   Publication Rights	32
	9.4   Restrictions on Material Non-Public Information	33
	Article X REPRESENTATIONS, WARRANTIES AND COVENANTS	33
	10.1   High Point’s Representations	33
	10.2   Calithera’s Representations	35
	10.3   Mutual Covenant	36
	10.4   No Warranty	36
	

    	iv

    	 

    

	Article XI INDEMNIFICATION	36
	11.1   Indemnification in Favor of High Point	36
	11.2   Indemnification in Favor of Calithera	37
	11.3   General Indemnification Procedures	37
	Article XII TERM AND TERMINATION	39
	12.1   Term	39
	12.2   Termination for Convenience	39
	12.3   Termination for Breach	39
	12.4   Termination for Insolvency	39
	12.5   Consequences of Certain Terminations by the Parties	40
	12.6   Payment of Balance of Quarterly Research Fees	44
	12.7   Unblock License	44
	12.8   Effect of Termination and Expiration; Accrued Rights and Obligations	45
	12.9   Survival	45
	Article XIII MISCELLANEOUS	45
	13.1   Governing Law	45
	13.2   Jurisdiction	45
	13.3   Waiver	46
	13.4   Notices	46
	13.5   Entire Agreement	47
	13.6   Headings	47
	13.7   Severability	47
	13.8   Registration and Filing of the Agreement	47
	13.9   Assignment	48
	13.10   Counterparts	48
	13.11   Force Majeure	48
	13.12   Press Releases and Other Disclosures	48
	13.13   Third Party Beneficiaries	49
	13.14   Relationship of the Parties	49
	13.15   Performance by Affiliates	49
	13.16   Construction	50
	13.17   No Consequential or Punitive Damages	50

    	v

    	 

    

LICENSE AND RESEARCH AGREEMENT

 

THIS LICENSE AND RESEARCH AGREEMENT
is entered into this 5th day of March, 2015 (the “Effective Date”) by and between Calithera Bioscience Inc.,
a corporation organized under the laws of the State of Delaware, having a business address at 343 Oyster Point Blvd #200, South
San Francisco, CA 94080 (“Calithera”), on the one hand, and High Point Pharmaceuticals, LLC, a company organized
under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 (“HPP”)
and TransTech Pharma LLC, a company organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall
Oaks Parkway, High Point, NC 27265 (“TransTech” and collectively with HPP, “High Point”),
on the other hand.

 

WHEREAS, High Point has developed or obtained
rights to High Point Patent Rights (as hereinafter defined) and High Point Know-How (as hereinafter defined);

 

WHEREAS, High Point has developed certain
Hexokinase Inhibitors (as hereinafter defined), and Calithera wishes to fund a research program that will include the development
of additional Hexokinase Inhibitors by High Point; and

 

WHEREAS, Calithera desires to obtain an exclusive
license under the High Point Patent Rights and the High Point Know-How to make and use such Hexokinase Inhibitors, and to develop
and commercialize Licensed Products (as hereinafter defined), under the terms and conditions set forth herein, and High Point desires
to grant such a license.

 

NOW, THEREFORE, the Parties agree as follows:

 

Article
I

Definitions

 

The following terms, whether used in the singular
or plural, shall have the following meanings:

 

1.1             
“Acceptable Human Exposure”. Acceptable Human Exposure means the demonstration of all of the following
in a clinical trial of a Licensed Product: (a) [***]; (b) [***]; and (c) [***].

 

1.2             
“Act”. Act means both the United States Federal Food, Drug, and Cosmetic Act, as amended from time to
time, and the regulations promulgated under the foregoing.

 

1.3             
“Affiliate”. Affiliate means any Person directly or indirectly controlled by, controlling or under common
control with, a Party, but only for so long as such control shall continue. For purposes of this definition, “control”
(including, with correlative meanings, “controlled by”, “controlling” and “under common control with”)
means, with respect to a Person, possession, direct or indirect, of (a) the power to direct or cause direction of the management
and policies of such Person (whether through ownership of securities or partnership or other ownership interests, by contract or
otherwise), or (b) at least 50% of the voting securities or other comparable equity interests of such Person.

 

    	 

    	 

    

1.4             
“Bankruptcy Code”. Bankruptcy Code means Title 11 of the United States Code, as amended from time to
time.

 

1.5             
“Business Day”. Business Day means a day that is not a Saturday, Sunday or a day on which banking institutions
in New York City, New York are authorized or required by Law to remain closed.

 

1.6             
“Calendar Quarter”. Calendar Quarter means each of the periods ending on March 31, June 30, September
30 and December 31 of any year.

 

1.7             
“Calendar Year”. Calendar Year means each calendar year during the Term.

 

1.8             
“Calithera-Derived Molecule”. Calithera-Derived Molecule means any Hexokinase Inhibitor that is (a) [***]
or [***], (b) [***] or [***] or [***], or (c) [***] or [***]. Notwithstanding the foregoing, Calithera-Derived Molecule [***] either
[***] or [***].

 

1.9             
“Calithera Intellectual Property”. Calithera Intellectual Property means the Calithera Know-How and the
Calithera Patent Rights.

 

1.10         
“Calithera Know-How”. Calithera Know-How means all Know-How that is Controlled by Calithera as of the
Effective Date or thereafter during the Term and that is necessary or reasonably needed to research, Develop or Manufacture any
Program Molecule or any Licensed Product.

 

1.11         
“Calithera Patent Rights”. Calithera Patent Rights means (a) all Patent Rights that are Controlled by
Calithera as of the Effective Date or thereafter during the Term and that is necessary or reasonably needed to research, Develop
or Manufacture any Program Molecule or any Licensed Product and (b) Program Patent Rights.

 

1.12         
“Clinical Candidate”. Clinical Candidate means a Program Molecule that:

 

(a)           is shown to have the following profile:

 

(i)                
[***]; or

 

(b)           is selected by Calithera as, or otherwise is, the subject of [***].

 

    	2

    	 

    

1.13         
“Combination Product”. Combination Product means (a) any pharmaceutical product that is a single formulation
consisting of a Program Molecule and one or more other active compounds or active ingredients, which other active compounds or
active ingredients are not another Program Molecule, are not Covered by a High Point Patent Right or Program Patent Right, and
do not embody any High Point Know-How, in all such cases prior to such other active compound or active ingredient (“Other
API”) being combined with such Program Molecule or (b) any combination of a Program Molecule sold together with any separately
formulated Other API for a single invoiced price.

 

1.14         
“Commercialization” or “Commercialize”. Commercialization or Commercialize means activities
directed to obtaining pricing and reimbursement approvals, marketing, promoting, distributing, importing or selling a product.
For purposes of clarity, Commercialization shall not include any activities related to Manufacturing.

 

1.15         
“Commercially Reasonable Efforts”. Commercially Reasonable Efforts means, with respect to a Program Molecule
or Licensed Product, the carrying out of obligations under this Agreement with those efforts and resources that a biotechnology
company of similar size and resources to Calithera would use were it Developing or Commercializing its own pharmaceutical products
that are of similar stage of Development or Commercialization or market potential as the Licensed Product, taking into account
product profile, product labeling or anticipated labeling, present and future market potential, strength and duration of patent
protection and anticipated exclusivity, past performance of Licensed Products, financial return, safety, efficacy and other medical
and clinical considerations, present and future regulatory environment and competitive market conditions, launching strategy and
other relevant scientific, technical, legal, operational and commercial factors, all as measured by the facts and circumstances
at the time such efforts are due.

 

1.16         
“Control” or “Controlled”. Control or Controlled means, with respect to any intellectual
property right or other intangible or tangible property, the possession (whether by ownership or license (other than pursuant to
this Agreement)) by a Party of the ability to grant to the other Party a license or sublicense or access as provided herein without
violating the terms of any agreement with any other Person.

 

1.17         
“Cover”, “Covering” or “Covered”. Cover, Covering
or Covered means, with respect to a product, technology, process or method that, in the absence of ownership of or a license granted
under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology,
process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such
Valid Claim if it were to issue).

 

1.18         
“Covered Period”. Covered Period means the period commencing on the Effective Date and ending on [***].

 

    	3

    	 

    

1.19         
“Development” or “Develop”. Development or Develop means pre-clinical and clinical
research and drug development activities, including toxicology and other pre-clinical development efforts, stability testing, process
development, formulation development, delivery system development, quality assurance and quality control development, statistical
analysis, clinical pharmacology, clinical studies (including pre- and post-approval studies and investigator sponsored clinical
studies), regulatory affairs, and Regulatory Approval and clinical study regulatory activities (excluding regulatory activities
directed to obtaining pricing and reimbursement approvals). For purposes of clarity, “Development” and “Develop”
excludes basic research, screening and discovery activities, including molecular biology, biochemistry and pre-clinical pharmacology,
directed to the identification of new compounds or molecules.

 

1.20         
“Development Plan”. Development Plan means the plan for the clinical Development of Licensed Products
in the Field in the Territory as it may be modified from time to time, from which Calithera may redact proprietary information
as well as information that is not relevant to Licensed Products.

 

1.21         
“Development Term”. Development Term means, with respect to a Program Molecule, the period commencing
on the Effective Date and ending as of the date of the First Commercial Sale of a Licensed Product containing such Program Molecule
to occur for any Indication in any Major Market.

 

1.22         
“EMA”. EMA means The European Medicines Agency and any successor agency thereto.

 

1.23         
“EU”. EU means the European Union, as it may be redefined from time to time.

 

1.24         
“FDA”. FDA means the United States Food and Drug Administration and any successor agency thereto.

 

1.25         
“Field”. Field means any therapeutic, prophylactic, preventative or diagnostic use.

 

1.26         
“First Commercial Sale”. First Commercial Sale means, with respect to a Licensed Product in a country,
the earlier of the issuance of the first invoice or the receipt of the first payment for a shipment of a Licensed Product in commercial
quantities for commercial sale by Calithera, its Affiliates or its Sublicensees to a Third Party after receipt of the first Regulatory
Approval for such Licensed Product in such country.

 

1.27         
“FTE”. FTE means a full-time equivalent person year (consisting of a total of [***] hours per year) of
scientific, technical or managerial (but not administrative) research work. An individual who works more than [***] hours in a
year will be treated as one FTE regardless of the number of hours worked.

 

1.28         
“FTE Rate”. FTE Rate means $275,000 per FTE.

 

    	4

    	 

    

1.29         
“GAAP”. GAAP means accounting principles generally accepted in the United States of America, as in effect
from time to time.

 

1.30         
“Generic Competition”. Generic Competition exists, with respect to a Licensed Product in any country
in the Territory in a given Calendar Quarter, if, during such Calendar Quarter, one or more Generic Products are commercially available
in such country.

 

1.31         
“Generic Product”. Generic Product means, with respect to a given Licensed Product, any pharmaceutical
product sold by a Third Party, not authorized by Calithera, its Affiliates or Sublicensees, that (a) contains as an active pharmaceutical
ingredient a Program Molecule included in such Licensed Product or a prodrug, metabolite, salt, ester, hydrate, solvate, polymorph,
stereoisomer, enantiomer, free acid form, crystal form, free base form, or racemate of such Program Molecule, and (b) is either
(i) approved for sale in reliance on, in whole or in part, the prior approval of such Licensed Product as determined by the applicable
Regulatory Authority, or (ii) is otherwise substitutable for such Licensed Product under applicable Laws by a pharmacist without
the intervention of the prescribing physician.

 

1.32         
“Governmental Authority”. Governmental Authority means any United States federal, state or local or any
foreign government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or
commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or
power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body.

 

1.33         
“Hexokinase Inhibitor”. Hexokinase Inhibitor means any Small Molecule having the following characteristic:
[***] assay described in Schedule 1.33.

 

1.34         
“High Point Intellectual Property”. High Point Intellectual Property means the High Point Know-How and
the High Point Patent Rights and all of High Point’s rights in the Joint Inventions and Joint Patents.

 

1.35         
“High Point Know-How”. High Point Know-How means any Know-How that is Controlled by High Point as of
the Effective Date or thereafter during the Term and that is necessary or reasonably needed to Develop, make, have made, use, sell,
offer for sale or import Program Molecules or Licensed Products.

 

1.36         
“High Point Molecule”. High Point Molecule means (a) any Hexokinase Inhibitor that is (i) Controlled
by High Point as of the Effective Date, (ii) disclosed or claimed in the High Point Patent Rights, or (iii) invented solely by
or on behalf of High Point in the conduct of the Research Program or (b) any other Small Molecule disclosed or claimed in the High
Point Patent Rights existing as of the Effective Date. For clarity, HPP399 is a High Point Molecule.

 

1.37         
“High Point Patent Rights”. High Point Patent Rights means (a) all Patent Rights that are Controlled
by High Point as of the Effective Date or thereafter during the Term that are necessary or reasonably needed to Develop, make,
have made, use, sell, offer for sale or import Program Molecules or Licensed Products and (b) High Point’s interest in the
Joint Patents. The High Point Patent Rights existing as of the Effective Date are set forth on Schedule 1.37.

 

    	5

    	 

    

1.38         
“HPP399”. HPP399 means the molecule identified by High Point using High Point’s internal reference
number 00309399, the structure of which High Point has disclosed to Calithera as of the Effective Date. For purposes of clarity,
HPP399 shall be deemed to be a Hexokinase Inhibitor.

 

1.39         
“IND”. IND means an investigational new drug application filed with the FDA with respect to a Licensed
Product, or equivalent application filed with the Regulatory Authority of a country in the Territory other than the United States.

 

1.40         
“IND Enabling GLP Toxicology Study”. IND Enabling GLP Toxicology Study means a toxicology (acute or sub-chronic),
genotoxicity, or safety pharmacology study that meets the requirements set forth in 21 C.F.R. Part 58 or comparable regulations
in countries outside the United States pertaining to good laboratory practice for use or intended for use in an IND, but excluding
any toxicology study performed in the course of evaluating compounds prior to the selection of a Clinical Candidate.

 

1.41         
“Indication”. Indication means the description of use of a Licensed Product in the treatment, prevention
or diagnosis of a recognized disease or condition as provided for in the Code of Federal Regulations (CFR) labeling requirements
in 21 CFR Part 201 – Labeling. For the purposes of this Agreement, a new Indication [***] or [***].

 

1.42         
“Initiation”. Initiation means, with respect to any Phase I Clinical Trial, Phase II Clinical Trial or
Phase III Clinical Trial, the date on which the first volunteer or patient in such trial has received his or her initial dose.

 

1.43         
“Know-How”. Know-How means proprietary, non-public information and materials, whether patentable or not,
including (a) ideas, discoveries, inventions, improvements or trade secrets, (b) pharmaceutical, chemical and biological materials,
products and compositions, (c) tests, assays, techniques, data, methods, procedures, formulas, or processes, (d) technical, medical,
clinical, toxicological and other scientific data and other information relating to any of the foregoing, and (e) drawings, plans,
designs, diagrams, sketches, specifications or other documents containing or relating to such information or materials.

 

1.44         
“Law” or “Laws”. Law or Laws means all laws, statutes, rules, regulations,
orders, judgments or ordinances of any Governmental Authority.

 

1.45         
“Legal Exclusivity”. Legal Exclusivity means, with respect to a Licensed Product and a country or region,
the right to exclude any Person who is not a Calithera Affiliate or a Sublicensee from Commercializing a product that could compete
with such Licensed Product in such country or region, either through (a) a Valid Claim included within a High Point Patent Right
Covering such Licensed Product in such country or region, or (b) data exclusivity rights, orphan drug designation, or such other
rights conferred by a Regulatory Authority or other applicable Governmental Authority in such country or region.

 

    	6

    	 

    

1.46         
“Licensed Product”. Licensed Product means any pharmaceutical preparation containing a Program Molecule,
including any Combination Product.

 

1.47         
“Losses”. Losses means any and all (a) claims, losses, liabilities, damages, fines, royalties, governmental
penalties, deficiencies, interest, awards, and judgments, (b) with respect to Third Parties, settlement amounts and all of the
items referred to in clause (a), and (c) in connection with all of the items referred to in clauses (a) and (b) above, any and
all costs and expenses (including reasonable attorney fees and all other out-of-pocket expenses reasonably incurred in investigating,
preparing or defending any litigation or proceeding, commenced or threatened).

 

1.48         
“Major EU Country”. Major EU Country means France, Germany, Italy, Spain or the United Kingdom.

 

1.49         
“Major Markets”. Major Markets means, collectively, the United States, the Major EU Countries and Japan,
and Major Market means any one of them.

 

1.50         
“Manufacture” or “Manufacturing”. Manufacture or Manufacturing means activities
directed to producing, manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release,
shipping and storage of a product.

 

1.51         
“Marketing Authorization”. Marketing Authorization means the act of a Regulatory Authority or other Governmental
Authority necessary for the marketing and sale of a Licensed Product in a particular Indication or Indications in a country in
the Territory, including, (a) in the case of the United States, the granting of Regulatory Approval, and, (b) in the case of a
country in the Territory other than the United States in which Pricing Approval is required, the granting of both Regulatory Approval
and Pricing Approval by the applicable Regulatory Authority or other Governmental Authority in such country. As used in this definition,
“Pricing Approval” means the approval or governmental decision establishing a price for a Licensed Product that
can be charged to consumers and will be reimbursed by the applicable Governmental Authority(ies) in such country.

 

1.52         
“MHLW”. MHLW means the Japanese Ministry of Health, Labour and Welfare and any successor agency thereto.

 

1.53         
“NDA”. NDA means a New Drug Application, as the case may be, as defined in the Act, filed with the FDA
with respect to a Licensed Product, or an equivalent application filed with the Regulatory Authority of a country in the Territory
other than the United States.

 

    	7

    	 

    

1.54         
“Net Sales”. Net Sales means the gross amounts invoiced (or, in the absence of an invoice, received)
by Calithera, its Affiliates and Sublicensees (each, a “Selling Party”) to any Third Party that is not a Sublicensee
with respect to sales of Licensed Products in the Territory, calculated in the same manner as reported in its audited financial
statements, less the sum of the following to the extent attributable to such sales:

 

(a)               
Discounts, credits, refunds, adjustments, retroactive price reductions, chargebacks and rebates actually allowed by Calithera,
its Affiliates or their Sublicensees directly for a Licensed Product, including those granted to managed healthcare organizations,
institutions or other buying groups, providers of healthcare or social and welfare systems;

 

(b)              
Sales, import, export, customs, value added taxes, tariffs, duties and other governmental charges and fees (including annual
fees due under Section 9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-148)) directly
imposed on the Licensed Products without reimbursement from any Third Party;

 

(c)               
Freight and insurance costs actually incurred by Calithera, its Affiliates or their Sublicensees directly on outbound shipping
of Licensed Products;

 

(d)              
Amounts actually allowed or credited on rejections or returns of sales of Licensed Products by Calithera, its Affiliates
or their Sublicensees, including returns by reason of a recall or corrective action;

 

(e)               
Amounts paid or credited to customers or third party distributors for inventory management, distribution, warehousing, and
related services to the extent consistent with industry standards;

 

(f)               
arm’s-length fees paid to Third Party consignees or agents in connection with the sale of the Licensed Product; and

 

(g)              
Amounts previously included in Net Sales of such Licensed Product that are written-off by Calithera, its Affiliates or Sublicensees
as uncollectible in accordance with GAAP.

 

Even if there is an overlap between any of
the deductions described in (a) through (g) above, each individual item shall only be deducted once in the overall Net Sales calculation.

 

Net Sales shall be determined from books and
records maintained in accordance with GAAP, consistently applied throughout the organization and across all products of the entity
whose sales of Licensed Product are giving rise to Net Sales. Licensed Products transferred for use in clinical or non-clinical
research and trials shall be excluded from Net Sales. Licensed Products sold or transferred in connection with compassionate sales
or use or indigent programs and Licensed Product samples shall not be counted toward Net Sales to the extent that such Licensed
Products are sold or transferred at or below fully burdened manufacturing and distribution costs. Licensed Products transferred
between Selling Parties shall not count toward Net Sales unless such Selling Party is an end-user of such Licensed Product.

 

    	8

    	 

    

In the event that Program Molecules are sold
or otherwise commercially disposed of as part of Combination Products, the Net Sales of such Combination Products, for purposes
of determining royalty payments, shall be determined, as to each unit of Combination Product sold or otherwise disposed of, by
multiplying (x) the Net Sales of the Combination Product (determined according to the method set forth above in this Section 1.54)
and (y) the Applicable Fraction determined in accordance with the following:

 

(i)                
Except as otherwise set forth in this Section 1.54, the “Applicable Fraction” shall be A/(A+B), where
A is the average wholesale price of the Product containing such Program Molecule as its only active ingredient when sold separately
in finished form and B is the average wholesale price of the other product containing Other API and not the Program Molecule (the
“Other Product”) sold separately in finished form.

 

(ii)              
In the event that the average wholesale price of the Licensed Product containing such Program Molecule as its only active
ingredient when sold separately in finished form can be determined but the average wholesale price of the Other Product when sold
separately in finished form cannot be determined, the “Applicable Fraction” shall be A/C, where A is the average
wholesale price of the Licensed Product containing such Program Molecule when sold separately in finished form and C is the average
wholesale price of the Combination Product.

 

(iii)            
In the event that the average wholesale price of the Other Product when sold separately in finished form can be determined
but the average wholesale price of the Licensed Product containing such Program Molecule as its only active ingredient when sold
separately in finished form cannot be determined, the “Applicable Fraction” shall be (C-D)/C, where D is the
average wholesale price of the Other Product when sold separately in finished form and C is the average wholesale price of the
Combination Product.

 

(iv)            
In the event that the average wholesale price of neither the Licensed Product containing such Program Molecule as its only
active ingredient when sold separately in finished form nor the Other Product when sold separately in finished form can be determined,
the “Applicable Fraction” shall be F/(F+G), where F is the fair market value of the Licensed Product containing
such Program Molecule as its only active ingredient contained in the Combination Product and G is the fair market value of all
Other APIs contained in the Combination Product, as reasonably determined in good faith by the Parties.

 

1.55         
“Objective Response”. Objective Response means the demonstration of [***] or [***] or [***] or [***]
or [***]. For the purposes of this Section 1.55, [***] will be based on [***] and [***] and [***]. For the avoidance of doubt,
any [***], or [***] will not be considered to have demonstrated [***] for the purposes of this Section 1.55.

 

    	9

    	 

    

1.56         
“Party”. Party means either HPP or TransTech, on the one hand or Calithera, on the other hand; “Parties”
means both HPP and TransTech, on the one hand and Calithera, on the other hand.

 

1.57         
“Patent Rights”. Patent Rights means the rights and interest in and to all issued patents and pending
patent applications in any country in the Territory, including all provisionals, divisionals, continuations, renewals, continuations-in-part,
patents of addition, re-examination, supplementary protection certificates, extensions, registrations or confirmation patents,
restoration of patent terms, letters of patent, and reissues thereof, and foreign counterparts of the foregoing.

 

1.58         
“Person”. Person means any natural person or any corporation, company, partnership, joint venture, firm,
Governmental Authority or other entity, including a Party.

 

1.59         
“Phase I Clinical Trial”. Phase I Clinical Trial means a human clinical trial in any country in the Territory
that would satisfy the requirements of 21 C.F.R. § 312.21(a).

 

1.60         
“Phase II Clinical Trial”. Phase II Clinical Trial means a human clinical trial in any country in the
Territory that would satisfy the requirements of 21 C.F.R. § 312.21(b).

 

1.61         
“Phase III Clinical Trial”. Phase III Clinical Trial means a human clinical trial in any country in the
Territory that would satisfy the requirements of 21 C.F.R. § 312.21(c).

 

1.62         
“Program Molecule”. Program Molecule means any (a) High Point Molecule or (b) Calithera-Derived Molecule.

 

1.63         
“Program Patent Rights”. Program Patent Right means (a) all Patent Rights that (i) are Controlled by
Calithera, (ii) disclose or claim (A) a composition of matter comprising a Hexokinase Inhibitor, (B) any use, or method of making
of any compound or molecule described in subsection (A), or (C) inventions, results, biomarkers, assays or formulations related
exclusively to Hexokinase Inhibitors or the use or testing, and (iii) are (A) conceived during the Covered Period by or on behalf
of Calithera or any of its Sublicensees, or (B) in-licensed by Calithera or any of its Sublicensees from a Third Party during any
portion of the Covered Period that is during the Term; and (b) Calithera’s interest in the Joint Patents. Notwithstanding
the foregoing, Program Patent Rights exclude all Patent Rights conceived by or on behalf of any Sublicensee prior to the Effective
Date or after termination or expiration of the applicable sublicense.

 

    	10

    	 

    

1.64         
“Regulatory Approval”. Regulatory Approval means the granting, whether through lapse of time or otherwise,
by the FDA or by a comparable Regulatory Authority of approval to market a drug product in a country in the Territory.

 

1.65         
“Regulatory Authority”. Regulatory Authority means any Governmental Authority, including the FDA, EMA
or MHLW, with responsibility for granting licenses or approvals (with the exception of price approvals) necessary for the marketing
and sale of pharmaceutical products in any country.

 

1.66         
“Research Plan”. Research Plan means the written plan generally describing the activities to be conducted
by or on behalf of High Point pursuant to the Research Program. The initial Research Plan is attached hereto as Schedule 1.66,
which may be amended from time to time as provided in Section 3.1.

 

1.67         
“Research Program”. Research Program means the conduct of the research activities described in the Research
Plan by or on behalf of High Point.

 

1.68         
“Research Program Term”. Research Program Term means the twelve (12) month period commencing on the Effective
Date and ending twelve (12) months after the Effective Date, unless earlier terminated pursuant to this Agreement. Calithera may
discontinue the Research Program, for any reason, with at least two months written notice. In no event will the Research Program
extend beyond twelve (12) months from the Effective Date without mutual agreement.

 

1.69         
“ROW”. ROW means all countries in the Territory other than the countries in the Major Markets.

 

1.70         
“Small Molecule”. Small Molecule means any organic compound or molecule with a molecular weight less
than three thousand (3000) atomic mass units, other than a protein or an antibody, but including peptides, peptide analogs, metabolites,
prodrugs, solvates, hydrates, esters, salts, isomers, stereoisomers, racemates, tautomers, and polymorphs thereof. A “protein”
refers to a sequence of ten (10) or more amino acids joined to each other by peptide bonds or modified peptide bonds.

 

1.71         
“Sublicensee”. Sublicensee means a Third Party that has been granted a sublicense under the rights granted
to Calithera pursuant to Section 2.1 of this Agreement, which rights include at least the rights to Develop a Licensed Product
or to Manufacture or Commercialize a Licensed Product. Third Parties that are permitted only to (a) distribute and resell a Licensed
Product, (b) re-package a Licensed Product for resale or (c) Manufacture a Licensed Product for supply to Calithera, its Affiliates
or its Sublicensees (and have no other rights to Develop or Commercialize such Licensed Product) are not “Sublicensees”.

 

1.72         
“Territory”. Territory means all countries of the world.

 

1.73         
“Third Party”. Third Party means any Person other than High Point or Calithera or any of their respective
Affiliates.

 

    	11

    	 

    

1.74         
“Valid Claim”. Valid Claim means a claim in the High Point Patent Rights that Covers the applicable Licensed
Product in a country and that has not (a) expired; (b) been disclaimed; (c) been cancelled or superseded, or if cancelled or superseded,
has been reinstated; (d) been revoked, held invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent
authority of competent jurisdiction over such claim in such country from which no further appeal has or may be taken; and (e) in
the case of a patent application, been pending for more than [***] after the date of its first priority filing.

 

1.75         
Additional Definitions. Each of the following definitions is set forth in the section of this Agreement indicated
below:

 

	Definition:	Section:
	1934 Act	Section 9.4
	Abandoned Calithera Patent	Section 12.5(e)(v)
	Abandoned Joint Patent	Section 8.2(c)
	Abandoned Patent	Section 8.2(b)
	Additional Territories	Section 8.2(b)
	Agents	Section 9.1
	Applicable Fraction	Section 1.54
	Assignor	Section 13.9
	Calithera	Preamble
	Calithera Parties	Section 11.2
	Calithera Sole Inventions	Section 8.1(a)
	Commercialization Plan	Section 5.2
	Confidential Information	Section 9.2
	Confidentiality Agreements	Section 9.2
	Courts	Section 13.2
	Defaulting Party	Section 12.3
	Development Forum or DF	Section 4.2(a)
	Effective Date	Preamble
	High Point	Preamble
	High Point Parties	Section 11.1
	High Point Sole Inventions	Section 8.1(a)
	HPP	Preamble
	House Marks	Section 12.5(f)
	Indemnified Party	Section 11.3(a)
	Indemnifying Party	Section 11.3(a)
	Infringement Claim	Section 8.3(a)
	Joint Inventions	Section 8.1(b)
	Joint Patents	Section 8.2(c)
	Other API	Section 1.12
	Other Product	Section 1.54
	Paragraph IV Claim	Section 8.8(a)
	Quarterly Research Fee	Section 7.2(a)
	Research Program Coordinator	Section 3.3
	Royalty Term	Section 7.6(e)
	

    	12

    	 

    

	Definition:	Section:
	Sole Inventions	Section 8.1(a)
	Term	Section 12.1
	Third Party Claims	Section 11.1
	Third Party Licenses	Section 7.6(d)
	TransTech	Preamble
	Unelected Patent	Section 8.2(b)

 

Article
II

GRANTS OF RIGHTS

 

2.1             
High Point Grants of Rights.

 

(a)               
License Grant. Subject to the terms and conditions of this Agreement, High Point hereby grants to Calithera an exclusive
(even as to High Point and its Affiliates, except as set forth in Section 2.2(a)), royalty-bearing right and license, under the
High Point Intellectual Property, to (i) Manufacture and use High Point Molecules to identify and synthesize Calithera-Derived
Molecules, (ii) Develop High Point Molecules and Calithera-Derived Molecules into Licensed Products, and (iii) make and have made,
use, offer for sale, sell, have sold, import and otherwise Commercialize or have Commercialized Program Molecules and Licensed
Products in the Field in the Territory; subject to Section 2.2(a).

 

    	13

    	 

    

(b)              
Sublicenses. Calithera shall have the right to grant sublicenses through multiple tiers under the licenses granted
to Calithera under Section 2.1(a) to its Affiliates and to Third Parties without High Point’s prior written approval but
with written notice to High Point, with such notice to be provided no later than ninety (90) days after the grant of each sublicense.
Calithera shall provide High Point with written notice of the termination or expiration of any sublicense granted to a Third Party
within thirty (30) days thereof. All sublicenses granted by Calithera hereunder shall be consistent with the terms and conditions
of this Agreement. Calithera shall remain liable for breaches by its Sublicensees of any sublicense agreement; provided that
in the event a breach by a Sublicensee under its sublicense causes Calithera to breach any of its obligations under this Agreement,
Calithera shall have the opportunity to cure as set forth in Section 12.3.

 

2.2             
Calithera Grants of Rights.

 

(a)               
License Grant. Subject to the terms and conditions of this Agreement, Calithera hereby grants to High Point a non-exclusive,
royalty-free right and license, with the limited right to sublicense and to have made as set forth in Section 2.2(b), under the
Calithera Intellectual Property and its rights under the High Point Intellectual Property as set forth in Section 2.1(a), solely
to conduct, on behalf of Calithera, High Point’s research responsibilities under the Research Program.

 

(b)              
Sublicenses. High Point shall have the right to grant sublicenses under the license granted to High Point under Section
2.2(a), to other Persons retained by High Point upon the prior written consent of Calithera, such consent not to be unreasonably
withheld, delayed or conditioned, in each case solely to perform High Point’s responsibilities under the Research Program
on High Point’s behalf. All permitted sublicenses of High Point hereunder shall include terms and covenants at least as favorable
to and for the benefit of Calithera as those provided by High Point in the following sections of this Agreement: Sections 2.2(b),
8.1(d), 9, 10.1(b) and 10.1(c). High Point shall remain liable for breaches by its sublicensees of any sublicense agreement; provided
that in the event a breach by such sublicensee under its sublicense causes High Point to breach any of its obligations under
this Agreement, High Point shall have the opportunity to cure as set forth in Section 12.3.

 

2.3             
Rights Retained by the Parties. Any rights of High Point or Calithera, as the case may be, not expressly granted
to the other Party under the provisions of this Agreement shall be retained by such Party, subject to Section 2.5. Without limiting
the generality of the foregoing and without limitation to Section 2.5, no right or license is granted under the High Point Intellectual
Property to access or use any compound or molecule that is not a Program Molecule.

 

2.4             
Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any Section of this Agreement,
including under Sections 2.1 and 2.2, are rights to “intellectual property” (as defined in Section 101(35A) of the
Bankruptcy Code). Each of High Point and Calithera hereby acknowledges that (a) copies of research data, (b) laboratory samples,
(d) product samples, (d) formulas, (e) laboratory notes and notebooks, (f) data and results related to clinical trials, (g) regulatory
filings and approvals, (h) rights of reference in respect of regulatory filings and approvals, (i) pre-clinical research data and
results, and (j) marketing, advertising and promotional materials, in each case that relate to such intellectual property, constitute
“embodiments” of such intellectual property pursuant to Section 365(n) of the Bankruptcy Code. Each Party shall retain
and may fully exercise all of its rights and elections under the Bankruptcy Code or equivalent legislation in any other jurisdiction.
Upon the bankruptcy of either Party, the other Party shall further be entitled to a complete duplicate of, or complete access to,
as appropriate, any such intellectual property, and such intellectual property, if not already in its possession, shall be promptly
delivered to such other Party, unless the Party in bankruptcy elects to continue, and continues, to perform all of its obligations
under this Agreement.

 

2.5             
Exclusivity. During the Term, neither High Point nor any of its controlled (as such word is defined in Section 1.2)
Affiliates shall, alone or in collaboration with any other Person, [***]. During the Term, High Point shall ensure that none of
its personnel or its controlled (as such word is defined in Section 1.2) Affiliates’ or their personnel (a) enable or assist
any other Affiliate of High Point or any Third Party with [***] or (b) disclose any Confidential Information relating to Hexokinase
Inhibitors to any Affiliate of High Point other than a controlled (as such word is defined in Section 1.2) Affiliate or an investor
in High Point that is subject to obligations of non-disclosure and non-use with respect thereto.

 

    	14

    	 

    

Article
III

RESEARCH

 

3.1             
General. Calithera shall lead, and pay all costs of, the research of Licensed Products in the Field in the Territory
hereunder. High Point shall use commercially reasonable efforts to perform the Research Program in accordance with the Research
Plan. The Research Plan may be amended from time to time by mutual agreement of the Parties.

 

3.2             
High Point FTE Commitments.

 

(a)               
During the first twelve (12) months of the Research Program Term, High Point shall provide [***] to four (4) FTEs to work
on the Research Program consistent with the timelines set forth in the Research Plan and Calithera shall fully fund the costs of
such FTEs at the FTE Rate as provided in Section 7.2. In no event shall Calithera be responsible for funding more than four (4)
FTEs per year. High Point shall be responsible for and shall provide sufficient resources, including reagents and disposables,
at High Point’s cost and expense, to complete all aspects of the Research Plan assigned to High Point, including synthesizing
any additional High Point Molecules; provided, however, that, except as set forth in the initial Research Plan attached
hereto as Schedule 1.64, High Point shall not be obligated to manufacture quantities of any Program Molecule beyond the
quantity needed for research purposes, which shall not exceed the greater of the amounts listed in the initial Research Plan or
[***] of each Program Molecule.

 

(b)              
High Point shall require by written agreement that all FTEs and all other High Point personnel, employees, and agents involved
in the Research Program have entered into confidentiality and invention assignment agreements that are consistent with the provisions
of this Agreement and shall be obligated to assign any rights they may have in any invention made during such work to High Point.

 

3.3             
Research Program Coordinators. Calithera and High Point each shall appoint a representative (each, a “Research
Program Coordinator”) to serve as the primary contact between the Parties with respect to the Research Program. Each
Party shall notify the other within thirty (30) days after the Effective Date of the appointment of its Research Program Coordinator
and shall notify the other Party as soon as practicable upon changing this appointment. The Research Program Coordinators shall
meet at least once per month during the Research Program Term or more frequently as agreed by the Parties to discuss the progress
of the Research Program and interim results. Such meetings may be by teleconference or in person, with each Party responsible for
its own travel expenses, at a location agreed by the Parties. Within thirty (30) days after the end of the first three (3) months
of the Research Program Term, and within thirty (30) days after the end of each three (3) month period thereafter, High Point’s
Research Program Coordinator shall provide a written report to Calithera’s Research Program Coordinator summarizing the status
and interim results of the Research Program.

 

    	15

    	 

    

3.4             
Calithera Contributions. Upon the reasonable request of High Point, Calithera may, but shall not be obligated to,
provide High Point with scientific, development or other expertise in connection with the performance by High Point of its responsibilities
under the Research Plan.

 

3.5             
High Point Assistance. During the [***] month period immediately following the Effective Date and again during the
[***] month period immediately following the Research Program Term, High Point shall provide Calithera reasonable assistance in
transitioning High Point’s Hexokinase Inhibitor program to Calithera at no additional cost other than reimbursement of High
Point’s reasonable related out-of-pocket expenses. High Point shall promptly execute all reasonable actions following Calithera’s
request so as not to delay any timelines set forth in the Research Plan or the Development Plan. Such assistance shall include
providing Calithera with copies of all tangible materials in High Point’s possession that are included in the High Point
Intellectual Property or that otherwise relate to High Point’s Hexokinase Inhibitor program (such as cancer cell lines and
assays), subject to High Point’s existing obligations to any applicable Third Party, and related information regarding High
Point’s Hexokinase Inhibitor program, and providing reasonable amounts of consultation regarding such materials and information
and the status of High Point’s Hexokinase Inhibitor program.

 

Article
IV

DEVELOPMENT

 

4.1             
General. Subject to the terms of this Agreement, including the requirements of ARTICLE VI, Calithera shall be solely
responsible for, and pay all costs of, the Development of Program Molecules and Licensed Products in the Field in the Territory,
and for Manufacture of all Program Molecules and Licensed Products to support such Development, and shall use Commercially Reasonable
Efforts to perform such Development in accordance with the Development Plan. Calithera will provide High Point with a summary clinical
Development Plan for the Program Molecules and Licensed Products prepared at least annually and updated as appropriate; such plans
may be redacted for proprietary information as well as information that is not relevant to Program Molecules or Licensed Products.

 

4.2             
Development Forum. The Parties hereby establish a forum for communications and discussions regarding the Development
Plan (the “Development Forum” or “DF”).

 

(a)               
Composition of the Development Forum. The Development Forum shall be comprised of an equal number of representatives
of each Party which, unless the Parties otherwise agree, shall be two (2) representatives of each Party. Each Party shall notify
the other within thirty (30) days after the Effective Date of the appointment of its representatives to the DF, which representative
shall have the requisite technical knowledge and experience to oversee Development of Program Molecules and Licensed Products and
the requisite seniority to make decisions regarding such Development on behalf of such Party. Each Party may change its representatives
to the DF from time to time in its sole discretion, effective upon notice to the other Party of such change. These representatives
shall have ongoing familiarity with and a technical understanding of the Development Plan activities. Additional representatives
or consultants may from time to time, by mutual consent of the Parties, be invited to attend DF meetings. The DF shall be chaired
by a representative of Calithera. Each Party shall bear its own expenses related to the attendance of such meetings by its representatives.

 

    	16

    	 

    

(b)              
Meetings. The DF shall meet in accordance with a schedule established by mutual written agreement of the Parties
or upon the reasonable request of Calithera, but no less frequently than [***] during the Development Term, with the location for
such meetings alternating between High Point and Calithera facilities in the United States (or such other location as may be agreed
by the Parties), with each Party paying for its own travel expenses. Alternatively, the DF may meet by means of teleconference,
videoconference or other similar communications equipment as the Parties may agree.

 

(c)               
Scope of Development Forum. The DF’s role shall be limited to communications and discussions regarding the
Development of Program Molecules and Licensed Products in the Field. Within such scope the DF may: (i) confer regarding the status
of Development Plan activities; (ii) review and discuss amendments to the Development Plan; and (iii) discuss such other matters
relating to the Development of Program Molecules and Licensed Products in the Field as either Party may bring before the DF. The
DF shall have no decision-making authority.

 

4.3             
Exchange of Information Regarding Development. During the Development Term, Calithera shall provide High Point, through
the DF, with information and data relating to Calithera’s Development of Program Molecules and Licensed Products in the Field.
In addition, Calithera shall, promptly upon request by High Point, provide High Point with additional information reasonably requested
by High Point relating to Calithera’s Development of Program Molecules and Licensed Products in the Field. Without limiting
the generality of the foregoing, at least [***] during the period after the Development Term for so long as Calithera continues
to Develop any Program Molecule or Licensed Product for an Indication (other than the Indication(s) for which the applicable Licensed
Product has received Regulatory Approval), Calithera shall provide High Point with a reasonably detailed report describing Calithera’s
Development activities and the summary results thereof with respect to all Program Molecules and Licensed Products. Notwithstanding
anything to the contrary, this Section 4.3 shall be subject in all respects to ARTICLE IX.

 

Article
V

COMMERCIALIZATION

 

5.1             
General. Subject to the terms of this Agreement, including the requirements of ARTICLE VI, Calithera shall be solely
responsible for, and pay all costs of, the Commercialization of Licensed Products in the Field in the Territory, and for Manufacture
of all Licensed Products to support such Commercialization.

 

    	17

    	 

    

5.2             
Commercialization Plans. During the Royalty Term with respect to each Licensed Product, Calithera shall provide High
Point at least once per year with a summary of the Commercialization activities to be conducted by or on behalf of Calithera and
its Affiliates and Sublicensees (to the extent known to Calithera) with respect to such Licensed Product in the Major Markets,
taken as a whole, during the next year (each such plan, a “Commercialization Plan”).

 

Article
VI

DILIGENCE

 

6.1             
Commercially Reasonable Efforts. During the Term, subject to Section 6.3, Calithera shall use Commercially Reasonable
Efforts to research, Develop, seek Marketing Authorizations for, Manufacture and Commercialize at least one Program Molecule and
Licensed Product in the Territory.

 

6.2             
Specific Efforts with Respect to Program Molecules and Licensed Products. Subject to Section 6.3, Calithera shall
achieve [***], by the corresponding deadlines (subject to Section 13.11) with respect to at least one Program Molecule or Licensed
Product set forth in the table below:

 

	Diligence Milestone	Deadline
	[***]	[***]

 

* For purposes of (b) above, [***] means a
[***] that:

 

[***]

 

For clarity, Calithera shall not be deemed
to be in breach of its obligations under this Section 6.2 for failure to meet a diligence milestone by the applicable deadline
if (A) such deadline has been extended pursuant to Section 6.3, (B) Calithera can demonstrate to High Point’s reasonable
satisfaction that Calithera is actively pursuing ongoing studies designed to achieve such diligence milestone by such extended
deadline, and (C) Calithera achieves such diligence milestone by such extended deadline (which may be subject to further extension
pursuant to Section 6.3).

 

6.3             
Failure to Meet Diligence Obligations. If Calithera fails to meet its obligations under Section 6.1 or 6.2 in any
material respect, then High Point shall notify Calithera of such failure and High Point shall have the right to terminate this
Agreement pursuant to Section 12.3 (subject to the opportunity to cure as set forth therein) in the case of a breach under Section
6.1 or Section 6.2. Notwithstanding the foregoing, if such failure is due to causes that are beyond the reasonable control of Calithera,
including due to regulatory action or delay, low patient enrollment, safety concerns, issues with chemistry, manufacturing and
controls (CMC), force majeure, delays due to an institutional review board, scientific or legal reasons or delays caused by High
Point, its Affiliates or a Third Party, notwithstanding Calithera’s good faith efforts to achieve those milestones, then,
if Calithera promptly notifies High Point in writing of any such delay and the cause and anticipated duration thereof, Calithera
not be deemed in default or breach of this Agreement and the deadlines for achieving those milestones will be deemed automatically
extended by the time of the delay reasonably attributable to such applicable causes.

 

    	18

    	 

    

Article
VII

FINANCIAL PROVISIONS

 

7.1             
Initial License Payment. Calithera shall make a one-time payment to HPP of Six Hundred Thousand Dollars ($600,000)
no later than thirty (30) days after the Effective Date as upfront consideration for the license granted hereunder.

 

7.2             
Research Program. On or prior to the fifth (5th) Business Day after the end of the first Calendar Quarter
following the Effective Date, HPP shall submit an invoice and Calithera shall pay HPP within twenty-five (25) days after receipt
of such invoice, a Quarterly Research Fee for the then-ended first Calendar Quarter of the Research Program Term or portion thereof,
as applicable. Thereafter, on the last day of each Calendar Quarter during the portion of the Research Program Term covered by
the Research Plan, HPP shall submit an invoice, and Calithera shall pay HPP within twenty-five (25) days after receipt of such
invoice, a Quarterly Research Fee for such Calendar Quarter of the Research Program Term. As used in this Agreement, “Quarterly
Research Fee” means the amount determined by multiplying the FTE Rate by the number of FTE hours to be contributed by
High Point pursuant to the Research Plan during the applicable Calendar Quarter or portion thereof of the Research Program Term.
For purposes of clarity, the maximum amounts payable by Calithera to HPP for FTEs annually, if High Point provides the maximum
of four (4) FTEs, is set forth in Schedule 7.2(a) and the minimum amounts payable by Calithera to HPP annually, if High
Point provides the minimum of [***] FTEs, is set forth in Schedule 7.2(b). The minimum and maximum Quarterly Research Fee
for each Calendar Quarter of the Research Program Term is set forth in Schedule 7.2(c).

 

7.3             
Development, Manufacturing and Commercialization Costs. As between the Parties, Calithera shall be solely responsible
for all costs of Developing, Manufacturing and Commercializing Licensed Products.

 

    	19

    	 

    

7.4             
Event Milestone Payments. Calithera shall make the non-refundable, non-creditable payments to HPP set forth below
not later than thirty (30) days after the earliest date on which the corresponding milestone event set forth below is first achieved
by a Licensed Product for a disease or condition in the Field:

 

	Milestone Event	Payment
	(a)[***]	$[***]
	(b)[***]	$[***]
	(c)[***]	$[***]
	(d)[***]	(i) $[***]
	(ii) $[***]
	(iii) $[***]
	(e)[***]	$[***]
	(f)[***]	$[***]
	(g)[***]	$[***]
	(h)[***]	$[***]
	(i)[***]	$[***]
	(j)[***]	$[***]
	(k)[***]	$[***]
	(l)[***]	$[***]
	(m)[***]	$[***]

 

For purposes of clarity, the milestone payments
set forth in this Section 7.4 shall be paid only once, upon the first achievement of the applicable milestone event by the first
Licensed Product to achieve such milestone event, except that, if Regulatory Approval is obtained for a first Licensed Product,
and Calithera or any of its Affiliates or Sublicensees subsequently commence Development of an additional Licensed Product, then
the milestones payments for each of the milestone events listed in Section 7.4(f) ([***]) through (m) ([***]) above shall be payable
at [***] of the corresponding milestone payment amount for the first subsequent Licensed Product that achieves such milestone event.
For purposes of clarity, the maximum potential payment by Calithera under this Section 7.4 for each milestone shall be one hundred
percent (100%) of each milestone payment set forth in (a) though (e) and [***] of each milestone payment set forth in (f) through
(m) (i.e., one hundred percent (100%) for the first Licensed Product to achieve such milestone and an additional [***] for
the second Licensed Product to achieve such milestone).

 

If, with respect to any particular Licensed
Product, a later-listed milestone event in Section 7.4 (other than milestone (d) and each of the milestones (h) through (m), namely
the [***] for additional Indication milestones) is achieved by such Licensed Product prior to the achievement by such Licensed
Product of an earlier-listed milestone event in Section 7.4 (other than milestone (d) and each of the milestones (h) through (m),
namely the [***] for additional Indication milestones), then the milestone payment for such earlier-listed milestone event for
such Licensed Product shall be due and payable simultaneously with the payment for achievement of such subsequent milestone event,
except that (x) [***] shall not be deemed to trigger any milestone payment [***], and (y) [***] shall not be deemed to trigger
any other milestone payment.

 

If Calithera elects to cease Development of
any Licensed Product, then the milestone payments previously made by Calithera under this Section 7.4 shall be fully creditable
against the achievement of such milestone by a subsequent Licensed Product.

 

    	20

    	 

    

7.5             
Sales Milestone Payments. In addition to all other amounts payable under this Agreement, Calithera shall make non-refundable,
non-creditable milestone payments to HPP related to the marketing and sale of Licensed Products in the Territory, in the amounts
provided below:

 

	Milestone Event	Payment
	(a) Aggregate Net Sales of a Licensed Product in the Territory of greater than $[***] in a Calendar Year	$[***]
	(b) Aggregate Net Sales of a Licensed Product in the Territory of greater than $[***] in a Calendar Year	$[***]
	(c) Aggregate Net Sales of a Licensed Product in the Territory of greater than $[***] in a Calendar Year	$[***]

 

For purposes of clarity, each of the milestone
payments set forth in this Section 7.5 shall be paid only once and the maximum potential payment by Calithera under this Section
7.5 for each milestone shall be equal to one hundred percent (100%) of each milestone payment. A maximum of one milestone event
specified in Section 7.5(a), (b), and (c) above will be payable by Calithera for any given Calendar Year. If two or more of such
milestone events are achieved in different Calendar Quarters in the same Calendar Year, then Calithera shall pay each corresponding
milestone payment within the time period specified in Section 7.7, but may credit any milestone payment previously made for such
Calendar Year against the subsequent milestone payment for the same Calendar Year, such that, for such subsequent milestone event,
Calithera shall only be obligated to pay the difference between the milestone payment for the subsequent event and the aggregate
of all other sales milestone payments made during such Calendar Year corresponding to the earlier event(s), and the earlier milestone
payments may become payable if and when achieved in a subsequent Calendar Year. If two or more of such milestone events are achieved
in the same Calendar Quarter, Calithera shall only be obligated to pay the greater of the corresponding milestone payments for
such Calendar Quarter and the earlier milestone payments may become payable if and when achieved in a subsequent Calendar Year.

 

For example, upon the first achievement of
the milestone event set forth in Section 7.5(a), Calithera shall make the $[***] payment in accordance with Section 7.7. If the
milestone event set forth in Section 7.5(b) is also achieved during the same Calendar Year, Calithera shall make the $[***] payment
for that milestone event in accordance with Section 7.7, but Calithera may credit the $[***] it paid for achievement of the milestone
event set forth in Section 7.5(a) against such amount resulting in a net payment of $[***]. In this example, each of the milestone
events set forth in Sections 7.5(a) and (c) would become payable in subsequent Calendar Years if and when it is achieved.

 

    	21

    	 

    

7.6             
Licensed Product Royalties. Calithera shall pay to HPP royalties on Net Sales of Licensed Products in the Territory
as follows:

 

	Calendar Year Net Sales of Licensed Products	Royalty Rate
	Less than or equal to $[***]	[***]%
	Greater than $[***] and less than or equal to $[***]	[***]%
	Greater than $[***] and less than or equal to $[***]	[***]%
	Greater than $[***]	[***]%

 

(a)               
Applicability of Royalty Rates to Net Sales in the Territory. Royalties under this Section 7.6 on aggregate Net Sales
of Licensed Products in the Territory in a Calendar Year shall be paid at the rate applicable to the portion of Net Sales within
each of the Net Sales levels during such Calendar Year. For example, if, during a Calendar Year, aggregate Net Sales of Licensed
Products were equal to $[***], then the royalties payable by Calithera under this Section 7.6 would be calculated by adding (i)
the royalties with respect to the first $[***] at the first-level percentage of [***] percent ([***]%) ($[***] × [***]
= $[***]), and (ii) the royalties with respect to the next $[***] at the second-level percentage of [***] percent ([***]%)
($[***] × [***] = $[***]), for a total royalty of $[***].

 

(b)              
Royalty Term. Calithera’s royalty obligations to HPP under this Section 7.6 shall commence on a country-by-country
and Licensed Product-by-Licensed Product basis upon the First Commercial Sale of such Licensed Product in such country and shall
expire on a country-by-country basis and Licensed Product-by-Licensed Product basis on the later of: (i) the expiration of Legal
Exclusivity for such Licensed Product in such country (the “Exclusivity Royalty Term”) or (ii) the tenth (10th)
anniversary of the date of the First Commercial Sale by Calithera or any of its Affiliates or Sublicensees to a non-Sublicensee
Third Party of such Licensed Product in such country (the “Royalty Term”). Upon expiration of the Royalty Term
for a given Licensed Product in a given country, Calithera’s license under Section 2.1(a) shall become fully paid-up and
perpetual with respect to Commercialization of such Licensed Product in such country.

 

(c)               
Royalty Adjustment for Generic Competition or Expiration of Exclusivity Royalty Term. If, with respect to a particular
Licensed Product in a particular country in a particular Calendar Quarter, the Exclusivity Royalty Term has expired, then the royalties
payable pursuant to this Section 7.6 may be reduced for such Calendar Quarter to the extent required to comply with applicable
Law, if any, governing royalties payable on Licensed Products after expiration of all issued High Point Patent Rights Covering
such Licensed Products, and provided, that (i) if the Generic Products have a market share during such Calendar Quarter
of more than [***] and less than or equal to [***] of the aggregate market share of the corresponding Licensed Product(s) and Generic
Product(s) (based on data provided by IMS International, or if such data is not available, such other reliable data source as reasonably
determined by Calithera and agreed by HPP (such agreement not to be unreasonably withheld)) as measured by unit sales, then the
royalty rate pursuant to Section 7.6(a) for such Licensed Product(s) in such country shall be reduced for such Calendar Quarter
to [***] of Net Sales, and (ii) if the Generic Product(s) have a market share of more than [***] (as calculated in the preceding
proviso) during such Calendar Quarter, then [***] royalty shall be payable under this Section 7.6 on Net Sales during such Calendar
Quarter of such Licensed Product(s) in such country.

 

    	22

    	 

    

(d)              
Third Party Licenses. If Calithera reasonably determines to obtain a patent or intellectual property license from
a Third Party that is required or reasonably needed to make, sell or use a Licensed Product in the Field in a given country (“Third
Party License”), then Calithera may offset [***] of any payments (including upfront payments, milestones and royalties)
paid under such Third Party License to obtain such rights for such Licensed Product in such country against royalties payable to
HPP hereunder in respect of Net Sales of such Licensed Product in such country; provided, however, in no event shall
such credit cause the royalties paid to HPP for any particular Calendar Quarter to be reduced to less than [***] of the amount
that would otherwise be payable to HPP for such Calendar Quarter pursuant to Section 7.6 with respect to such Licensed Product
in such country. Notwithstanding the foregoing provisions of this Section 7.6(d), [***] to the extent any Third Party Licenses
relate to [***].

 

(e)               
Aggregate Royalty Reductions. Notwithstanding anything to the contrary in this Section 7.6, in no event shall the
royalties otherwise payable under Section 7.6(a) with respect to any given Net Sales of a Licensed Product in a country in the
Territory be reduced as a result of the royalty reduction provisions of Sections 7.6(c) and (d) to be less than [***].

 

7.7             
Reports; Payments. Within [***] days after the end of each Calendar Quarter other than the last Calendar Quarter
of Calithera’s fiscal year, and within [***] days after the end of the last Calendar Quarter of Calithera’s fiscal
year, in which there are Net Sales giving rise to a payment obligation under Section 7.5 or 7.6, Calithera shall submit to HPP
a report identifying, for each Licensed Product, the gross amount of sales of such Licensed Product for each country for such Calendar
Quarter and the resulting royalties and the sales milestone payable to HPP, including a description of any deductions made from
the gross amount of sales to calculate Net Sales and any royalty reductions made as a result of Sections 7.6(d) and 7.6(e). Concurrently
with each such report, Calithera shall pay to HPP all royalties and sales milestones payable by it under Sections 7.5 and 7.6.

 

7.8             
Books and Records; Audit Rights. Calithera shall keep complete and accurate records of the underlying revenue and
expense data relating to the calculations of Net Sales and payments required by Sections 7.5 and 7.6. HPP shall have the right,
once annually at its own expense, to have an independent, certified public accounting firm, selected by HPP and reasonably acceptable
to Calithera, review any such records of Calithera in the location(s) where such records are maintained by Calithera upon reasonable
notice (which shall be no less than thirty (30) days prior notice) and during regular business hours and under obligations of strict
confidence, for the sole purpose of verifying the basis and accuracy of payments made under Sections 7.5 and 7.6 within the [***]
period preceding the date of the request for review. The report of such accounting firm shall be limited to a certificate stating
whether any report made or payment submitted by Calithera during such period is accurate or inaccurate and the actual amounts of
Net Sales and royalties due for such period. Calithera shall receive a copy of each such report concurrently with receipt by HPP.
Should such inspection lead to the discovery of a discrepancy to HPP’s detriment, Calithera shall pay within fifteen (15)
Business Days after its receipt from the accounting firm of the certificate the amount of the discrepancy. HPP shall pay the full
cost of the review unless the underpayment of royalties is greater than [***] of the amount due for the applicable period, in which
case Calithera shall pay the reasonable cost charged by such accounting firm for such review. Any overpayment of royalties by Calithera
revealed by an examination shall be fully creditable against future royalty payments.

 

    	23

    	 

    

7.9             
Taxes. HPP shall pay any and all taxes levied on account of all payments it receives under this Agreement. If laws
or regulations require that taxes be withheld, Calithera will (a) deduct those taxes from the remittable payment, (b) timely pay
the taxes to the proper taxing authority, and (c) send proof of payment to HPP within thirty (30) days after receipt of confirmation
of payment from the relevant taxing authority. Calithera will reasonably cooperate with HPP to obtain the benefit of any applicable
tax law or treaty, including the pursuit of any refund or credit of such tax to HPP.

 

7.10         
Payment Method and Currency Conversion. All payments to be made by Calithera to HPP shall be in immediately available
funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer,
at Calithera’s election, to HPP’s bank account at [***], or to such other bank account as HPP shall designate in a
notice at least ten (10) days before the payment is due. HPP’s wiring instructions are set forth on Schedule 7.10.
For the purposes of determining the amount of any sales milestone payment under Section 7.5 or royalties due for the relevant Calendar
Quarter under Section 7.6, the amount of Net Sales in any foreign currency shall be converted into United States dollars in a manner
consistent with Calithera’s normal practices used to prepare its audited financial reports; provided that such practices
use a widely accepted source of published exchange rates. Upon request by HPP, Calithera shall disclose the source for the rates
of exchange used.

 

7.11         
Blocked Payments. If by reason of applicable Laws in any country in the Territory, it becomes impossible or illegal
for Calithera or its Affiliates or Sublicensees to transfer, or have transferred on its behalf, milestones, royalties or other
payments to HPP, Calithera shall promptly notify HPP of the conditions preventing such transfer and such milestones, royalties
or other payments shall be deposited in local currency in the relevant country to the credit of HPP in a recognized banking institution
designated by HPP or, if none is designated by HPP within a period of thirty (30) days, in a recognized banking institution selected
by Calithera or its Affiliate or Sublicensee, as the case may be, and identified in a notice given to HPP. If so deposited in a
foreign country, Calithera shall provide, or cause its Affiliate or Sublicensee to provide, reasonable cooperation to HPP so as
to allow HPP to assume control over such deposit as promptly as practicable.

 

7.12         
Late Payments. If a Party shall fail to make a timely payment pursuant to the terms of this Agreement, interest shall
accrue on the past due amount as follows:

 

(a)               
for amounts thirty (30) or fewer days past due, the rate applied shall be the thirty (30) day U.S. dollar LIBOR rate effective
for the date that payment was due (as published in the Wall Street Journal), computed for the actual number of days the payment
was past due; and

 

(b)              
for amounts greater than thirty (30) days past due, the rate applied shall be the thirty (30) day U.S. dollar LIBOR rate
effective for the date that payment was due (as published in the Wall Street Journal) plus [***] per annum, computed for the actual
number of days the payment was past due.

 

    	24

    	 

    

Article
VIII

INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION

AND RELATED MATTERS

 

8.1             
Ownership of Inventions.

 

(a)               
Sole Inventions. Each Party shall exclusively own all inventions made solely by such Party, its employees, agents
and consultants (“Sole Inventions”). Sole Inventions made solely by Calithera, its employees, agents and consultants
are referred to herein as “Calithera Sole Inventions”. Sole Inventions made solely by High Point, its employees,
agents and consultants shall be solely owned by HPP and are referred to herein as “High Point Sole Inventions”.

 

(b)              
Joint Inventions. Calithera and HPP shall jointly own all inventions made jointly by employees, agents and consultants
of Calithera, on the one hand, and employees, agents and consultants of High Point, on the other hand, on the basis of each of
Calithera and HPP having one-half of an undivided interest in the whole (“Joint Inventions”). Each Party, on
behalf of itself and its Affiliates and permitted sublicensees, hereby assigns, agrees to assign or causes to be assigned sufficient
of its and its Affiliates’ and its permitted sublicensees’ right, title and interest in, to and under any Joint Invention
as necessary to effect the foregoing joint ownership allocation or any other assignment or license obligation under this Agreement
with respect to such Joint Invention. HPP hereby acknowledges and agrees that all of its right, title and interest in, to and under
Joint Inventions shall become part of the High Point Intellectual Property and subject to the license set forth in Section 2.1(a).

 

(c)               
Inventorship. For purposes of determining whether an invention is a Calithera Sole Invention, a High Point Sole Invention
or a Joint Invention, and for purposes of determining inventions with respect to Program Patent Rights, questions of inventorship
shall be resolved in accordance with United States patent Laws.

 

(d)              
Further Assurances. Each Party shall, and shall cause its Affiliates and permitted sublicensees to, enter into assignment
agreements pre-approved and reasonably acceptable to the other Party with Persons involved in the Research Program to obtain such
automatic assignment of future inventions, and shall execute all documents necessary to effect such assignment.

 

    	25

    	 

    

8.2             
Prosecution and Maintenance of Patent Rights.

 

(a)               
Prosecution of Calithera Patent Rights. Except as set forth in Section 12.5(e)(iv), Calithera shall have the sole
right to prepare, file, prosecute and maintain the Calithera Patent Rights (including the Program Patent Rights) other than the
Joint Patents.

 

(b)              
Prosecution of High Point Patent Rights. In accordance with this Section 8.2(b), unless Calithera and HPP otherwise
agree in writing and for so long as Calithera retains exclusive rights hereunder, Calithera shall have the right, but not the obligation,
and High Point shall reasonably cooperate, with respect to, the preparation, filing, prosecution and maintenance of the High Point
Patent Rights (other than the Joint Patents), using Foley Hoag LLP or other counsel of Calithera’s choice reasonably acceptable
to HPP. The out-of-pocket costs and expenses incurred to prepare, file, prosecute and maintain such High Point Patent Rights shall
be [***]. Calithera shall notify HPP at least forty-five (45) days prior to the deadline for entering into national phase with
respect to any PCT application included in such High Point Patent Rights and identify the countries or regions Calithera intends
to enter. No later than fifteen (15) days after receiving notice from Calithera of its intent to enter into national phase, HPP
shall provide Calithera with a list of any additional countries or regions (“Additional Territories”) in which
HPP would like Calithera to file and Calithera shall consider such list in good faith. If Calithera elects to not enter the national
phase in one or more Additional Territories, HPP may elect to enter the national phase in such Additional Territories [***], any
such application or patent (the “Unelected Patent”) shall [***], and HPP shall have the sole right, but not
the obligation, to prepare, file, prosecute and maintain such Unelected Patent.

 

HPP shall have access to all documentation,
filings and communications to or from the respective patent offices, at reasonable times and upon reasonable written notice (which
notice may be in e-mail). Calithera shall keep HPP informed of the status of all pending patent applications that pertain to any
Program Molecule or any Licensed Product. Calithera, its agents and attorneys shall consider in good faith comments of HPP regarding
any aspect of such patent prosecutions. In the event that HPP believes that such patent strategy would have an unreasonable, adverse,
economic effect on High Point’s rights under this Agreement (including inventorship or the value of any rights that HPP may
obtain under Section 12.5), HPP may elect to submit the dispute to an independent Third Party patent counsel mutually agreed by
Calithera and HPP, at HPP’s cost and expense. If such patent counsel determines that such patent strategy would have an unreasonable,
adverse economic effect on High Point’s rights under this Agreement (including inventorship or the value of any rights that
HPP may obtain under Section 12.5), then Calithera shall incorporate comments and adjust patent strategy as advised by such independent
Third Party patent counsel, and Calithera shall [***]. If Calithera determines to abandon any High Point Patent Right (other than
a Joint Patent) in all or any portion of the Territory (the “Abandoned Patent”), Calithera shall notify HPP
of such determination, no later than thirty (30) days before any deadline for further action to avoid abandonment. If HPP wishes
to continue to prosecute and maintain the Abandoned Patent, Calithera shall have the option to continue to prosecute and maintain
the Abandoned Patent or allow HPP to have the sole right, but not the obligation, to continue to prosecute and maintain the Abandoned
Patent [***], which for purposes of clarity, shall [***] set forth in this Agreement. If HPP is prosecuting and maintaining the
Abandoned Patent and High Point determines to abandon such Abandoned Patent, the foregoing rights of HPP set forth in this Section
8.2(a) shall apply to Calithera mutatis mutandis. Notwithstanding anything to the contrary, Calithera shall have the option
to regain control of prosecution and maintenance of an Abandoned Patent at any time, subject to [***] and [***] for such Abandoned
Patent. If either Calithera or HPP elects to maintain any Abandoned Patent or Unelected Patent, the other shall reasonably cooperate
to transfer such maintenance and prosecution thereof.

 

    	26

    	 

    

(c)               
Prosecution of Joint Patents. Calithera shall be responsible for obtaining, preparing, filing, prosecuting and maintaining
Patent Rights, in appropriate countries in the Territory, including the countries reasonably requested by HPP, Covering Joint Inventions
(“Joint Patents”). The out-of-pocket costs and expenses incurred to obtain, prosecute and maintain Joint Patents
shall be [***]. Calithera shall keep HPP informed of the status of all pending Joint Patents. In the event that HPP believes that
such patent strategy would have an unreasonable, adverse, economic effect on High Point’s rights under this Agreement (including
inventorship or the value of any rights that HPP may obtain under Section 12.5), HPP may elect to submit the dispute to an independent
Third Party patent counsel mutually agreed by Calithera and HPP, at HPP’s cost and expense. If such patent counsel determines
that such patent strategy would have an unreasonable, adverse economic effect on High Point’s rights under this Agreement
(including inventorship or the value of any rights that HPP may obtain under Section 12.5), then Calithera shall incorporate comments
and adjust patent strategy as advised by such independent Third Party patent counsel, and Calithera shall [***]. Calithera shall
not abandon any Joint Patent without at least thirty (30) days’ prior notice to HPP. If Calithera determines to abandon any
Joint Patent in all or any portion of the Territory (the “Abandoned Joint Patent”), Calithera shall notify HPP
of such determination. If HPP wishes to continue to prosecute and maintain the Abandoned Joint Patent, Calithera shall have the
option to continue to prosecute and maintain the Abandoned Joint Patent at its expense or allow HPP to have the sole right, but
not the obligation, to continue to prosecute and maintain the Abandoned Joint Patent [***]. Notwithstanding anything to the contrary,
Calithera shall have the option to regain control of prosecution and maintenance of an Abandoned Joint Patent at any time, subject
to [***] and [***] for such Abandoned Joint Patent. If Calithera or HPP elects to continue to prosecute and maintain any Abandoned
Joint Patent, the other shall reasonably cooperate to transfer prosecution and maintenance of such Abandoned Joint Patent.

 

(d)              
The Parties acknowledge that Calithera has the right, but not the obligation, at its sole discretion, to submit applicable
High Point Patent Rights, Calithera Patent Rights and Joint Patents, and other relevant patent information, to all applicable Governmental
Authorities for listing in the Orange Book or any similar listing or statutory or regulatory requirement in any country or regulatory
jurisdiction outside the United States. High Point or its Affiliates, as applicable, shall provide, [***], all support reasonably
necessary for Calithera to exercise its rights under this Section 8.2(d). “Orange Book” means the United States
Food and Drug Administration publication titled, “Approved Drug Products with Therapeutic Equivalence Evaluations”,
as it may be amended from time to time.

 

    	27

    	 

    

8.3             
Third Party Infringement.

 

(a)               
Notice. Each Party shall promptly report in writing to the other Party during the Term any known or suspected (i)
infringement of any of the High Point Patent Rights (including any Abandoned Patent or Unelected Patent) or Joint Patents (including
any Abandoned Joint Patent), or (ii) unauthorized use or misappropriation of any of the High Point Know-How or Know-How in Joint
Inventions (an “Infringement Claim”) of which such Party becomes aware, and shall provide the other Party with
all available evidence supporting such known or suspected infringement or unauthorized use.

 

(b)              
Initial Right to Enforce. Calithera shall have the sole right to enforce the Calithera Patent Rights (including the
Program Patent Rights) other than the Joint Patents. Calithera shall have the first right, but not the obligation, to initiate
a suit or take other appropriate action that it believes is reasonably required to protect (i.e., prevent or abate actual or threatened
infringement or misappropriation of) or otherwise enforce the High Point Intellectual Property (including any Abandoned Patent
or Unelected Patent), and the Parties’ rights in Joint Inventions and Joint Patents (including any Abandoned Joint Patent).
Any suit by Calithera shall be either in the name of HPP or its Affiliate, the name of Calithera or its Affiliate, or jointly by
Calithera, Calithera’s Affiliate(s), HPP and HPP’s Affiliate(s), as may be required by the Law of the forum. For this
purpose, High Point shall execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested
by Calithera; provided that [***] in connection with such cooperation.

 

(c)               
Step-In Right. If Calithera does not initiate a suit or take other appropriate action that it has the initial right
to initiate or take pursuant to Section 8.3(b) with respect to the High Point Patent Rights (including any Abandoned Patent or
Unelected Patent), Joint Patents (including any Abandoned Joint Patent), High Point Know-How or Know-How in Joint Inventions, against
a Third Party as to which the Infringement Claim concerns a product for which a Third Party is seeking or has received marketing
approval from the FDA or a corresponding foreign regulatory authority, HPP may provide Calithera with notice of HPP’s intent
to initiate a suit or take other appropriate action. If HPP provides such notice and Calithera does not initiate a suit or take
other appropriate action to protect the High Point Patent Rights (including any Abandoned Patent or Unelected Patent), Joint Patents
(including any Abandoned Joint Patent), High Point Know-How or Know-How in Joint Inventions within sixty (60) days after receipt
of such notice from HPP, then HPP shall have the right to initiate a suit or take such other appropriate action that HPP believes
is reasonably required to protect the High Point Patent Rights (including any Abandoned Patent or Unelected Patent), Joint Patents
(including any Abandoned Joint Patent), High Point Know-How or Know-How in Joint Inventions. Any suit by HPP shall be either in
the name of HPP or its Affiliate, the name of Calithera or its Affiliate, or jointly by Calithera, Calithera’s Affiliate(s),
HPP and HPP’s Affiliate(s), as may be required by the Law of the forum. For this purpose, Calithera shall execute such legal
papers and cooperate in the prosecution of such suit as may be reasonably requested by HPP; provided that [***] in connection
with such cooperation.

 

    	28

    	 

    

(d)              
Conduct of Certain Actions; Costs. The Party initiating suit shall have the sole and exclusive right to select counsel
for any suit initiated by it pursuant to Section 8.3(b) or 8.3(c). The initiating Party shall assume and pay all of its own out-of-pocket
costs incurred in connection with any litigation or proceedings initiated by it pursuant to Sections 8.3(b) and 8.3(c), including
the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in
any such suit by its own counsel at its own expense.

 

(e)               
Recoveries. In the event a Party assumes control over enforcing any Infringement Claim, the other Party (which, in
the case of High Point, shall be HPP) shall be entitled to [***] any damages, settlements, accounts of profits, or other financial
compensation recovered from a Third Party based upon any such Infringement Claim after deducting from the amount recovered the
controlling Party’s actual out-of-pocket expenses (including reasonable counsel fees and expenses) incurred in pursuing
such Infringement Claim, and the controlling Party may retain the balance.

 

8.4             
Patent Invalidity Claim. Each of the Parties shall promptly notify the other in the event of any legal or administrative
action by any Third Party against a High Point Patent Right (including an Abandoned Patent or Unelected Patent) or Joint Patent
(including an Abandoned Joint Patent) of which it becomes aware, including any nullity, revocation, reexamination, inter partes
review, post-grant review, opposition, interference, derivation or compulsory license proceeding. Calithera shall have the sole
right to defend against any such action involving a Calithera Patent Right or Program Patent Right. Calithera shall have the first
right, but not the obligation, to defend against any such action involving a High Point Patent Right (including an Abandoned Patent
or Unelected Patent) or Joint Patent (including an Abandoned Joint Patent) using counsel of its choice and the costs of any such
defense shall be [***]. High Point, upon request of Calithera, agrees to join in any such action and to cooperate reasonably with
Calithera; provided that [***] in connection with such cooperation. If Calithera does not defend against any such action
involving such Patent Right, then HPP shall have the right, but not the obligation, to defend such action and any such defense
shall be [***]. Calithera, upon request of HPP, agrees to join in any such action and to cooperate reasonably with HPP; provided
that [***] in connection with such cooperation.

 

8.5             
Patent Term Extensions. Calithera shall have the exclusive right, and shall use Commercially Reasonable Efforts,
to seek patent term extensions or supplemental patent protection, including supplementary protection certificates, in any country
in the Territory in relation to the Licensed Products [***]. High Point and Calithera shall cooperate in connection with all such
activities, and Calithera, its agents and attorneys will give due consideration to all timely suggestions and comments of HPP regarding
any such activities; provided that all final decisions shall be made by Calithera.

 

    	29

    	 

    

8.6             
Patent Marking. Calithera shall comply with the patent marking statutes in each country in which the Licensed Product
is sold by Calithera, its Affiliates or its Sublicensees.

 

8.7             
Interpretation of Patent Judgments. If any claim relating to a patent under the High Point Patent Rights (including
an Abandoned Patent or Unelected Patent) or Joint Patent (including an Abandoned Joint Patent) becomes the subject of a judgment,
decree or decision of a court, tribunal, or other authority of competent jurisdiction in any country, which judgment, decree, or
decision is or becomes final (there being no further right of review) and adjudicates the validity, enforceability, scope, or infringement
of the same, the construction of such claim in such judgment, decree or decision shall be followed thereafter in such country in
determining whether a product is a Licensed Product hereunder, not only as to such claim but also as to all other claims in such
country to which such construction reasonably applies. If at any time there are two or more conflicting final judgments, decrees,
or decisions with respect to the same claim, the decision of the higher tribunal shall thereafter control, but if the tribunals
be of equal rank, then the final judgment, decree, or decision more favorable to such claim shall control unless and until the
majority of such tribunals of equal rank adopt or follow a less favorable final judgment, decree, or decision, in which event the
latter shall control.

 

8.8             
Certification under Drug Price Competition and Patent Restoration Act.

 

(a)               
Notice. If a Party becomes aware of any certification filed pursuant to 21 U.S. C. § 355(b)(2)(A) or 355(j)(2)(A)(vii)(IV)
(or any amendment or successor statute thereto) claiming that any High Point Patent Rights (including an Abandoned Patent or Unelected
Patent) Covering a Licensed Product in the Field or Joint Patents (including an Abandoned Joint Patent), are invalid or otherwise
unenforceable, or that infringement will not arise from the manufacture, use, import or sale of a product by a Third Party (a “Paragraph
IV Claim”), such Party shall promptly notify the other Party in writing within five (5) Business Days after its receipt
thereof.

 

    	30

    	 

    

(b)              
Control of Response. Calithera shall have the right, but not the obligation, to initiate patent infringement litigation
for such Paragraph IV Claim, [***]. If Calithera elects not to assume control over enforcing any Paragraph IV Claim, Calithera
shall notify HPP as soon as practicable but in any event not later than ten (10) days before the first action required to enforce
or preserve such Paragraph IV Claim so that HPP may, but shall not be required to, assume sole control over enforcing such Paragraph
IV Claim using counsel of its own choice. The Parties shall reasonably cooperate in the prosecution of any Paragraph IV Claim,
and share any compensation recovered as a result of such prosecution, as set forth in Section 8.3(e) above; provided that
[***] in connection with such cooperation.

 

8.9             
Consents as to Joint Inventions and Joint Patents.

 

(a)               
During the Term, (i) High Point hereby consents to Calithera having the sole right and authority to control the licensing
of the Joint Inventions and Joint Patents and having the rights to prepare, file, prosecute and maintain the Joint Inventions and
Joint Patents in accordance with Section 8.2(c), and to enforce the Joint Patents in accordance with Section 8.3, and (ii) Calithera
hereby consents to High Point having the right to enforce the Joint Patents in accordance with Section 8.3(c).

 

(b)              
Following the Term:

 

(i)                
Subject to High Point’s rights under Section 12.5, High Point hereby consents to Calithera having the sole right to
control the licensing of and prepare, file, prosecute and maintain the Joint Inventions and Joint Patents in accordance with Section 8.2(c).

 

(ii)              
If HPP elects to receive the license set forth in Section 12.5(e)(ii), Calithera hereby consents to HPP thereafter having
the sole right and authority to control the licensing of the Joint Inventions and Joint Patents solely to make, have made, use,
sell, offer for sale and import the Program Molecules and Licensed Products in the Territory and having the rights to prepare,
file, prosecute and maintain the Joint Inventions and Joint Patents in accordance with Sections 8.2(c) and 12.5(e)(v), and to enforce
the Joint Patents in accordance with Section 12.5(e)(iii).

 

(iii)            
Subject to the rights set forth in subclause (ii) above, Calithera and HPP shall mutually agree on the roles and responsibilities
after the Term of each of them with respect to the enforcement of Joint Inventions and Joint Patents prior to either of them seeking
to enforce any Joint Invention or Joint Patent.

 

Article
IX

CONFIDENTIAL INFORMATION

 

9.1             
Treatment of Confidential Information. During the Term and for [***] years thereafter, each Party shall maintain
Confidential Information (as defined in Section 9.2) of the other Party in confidence, and shall not disclose, divulge or otherwise
communicate such Confidential Information to others (except for agents, directors, officers, employees, consultants, Affiliates
and advisors (collectively, “Agents”) under obligations of confidentiality no less stringent than those contained
herein) or use it for any purpose other than in connection with the conduct of the Research Program, or the Development, Manufacture
or Commercialization of Program Molecules or Licensed Products pursuant to this Agreement, and each Party shall exercise reasonable
efforts to prevent and restrain the unauthorized disclosure of such Confidential Information by any of its Agents, which reasonable
efforts shall be at least as diligent as those generally used by such Party in protecting its own confidential and proprietary
information. Each Party will be responsible for a breach of this ARTICLE IX by its Agents. For clarity, Calithera may disclose
Confidential Information of High Point (a) to Governmental Authorities (i) to the extent desirable to obtain or maintain INDs or
Regulatory Approvals for any Program Molecule or Licensed Product within the Territory and (ii) in order to respond to inquiries,
requests or investigations by Governmental Authorities; (b) to outside consultants, scientific advisory boards, managed care organizations,
and non-clinical and clinical investigators to the extent necessary to Develop or Commercialize any Program Molecule or Licensed
Product; and (c) to the extent desirable to obtain Program Patent Rights to protect, or to Develop or Commercialize, any Program
Molecule or Licensed Product; provided that Calithera shall obtain the same confidentiality obligations from such Third
Parties as it obtains with respect to its own similar types of confidential information.

 

    	31

    	 

    

9.2             
Confidential Information. “Confidential Information” means all trade secrets or other proprietary
information, including any proprietary data and materials (whether or not patentable or protectable as a trade secret), regarding
a Party’s or its licensor’s technology, products, business, financial status or prospects or objectives regarding the
Licensed Products, which is disclosed by a Party to the other Party. All information disclosed prior to the Effective Date by HPP
to Calithera pursuant to the confidentiality agreement between Calithera and HPP dated as of June 24, 2014, the confidentiality
agreement between Calithera and HPP dated as of August 12, 2014, as amended on September 30, 2014, or the material transfer agreements
between Calithera and HPP, dated September 30, 2014 and November 5, 2014 (collectively, the “Confidentiality Agreements”)
shall be deemed “Confidential Information” of High Point and all information disclosed prior to the Effective Date
by Calithera to High Point pursuant to the Confidentiality Agreements and all results from the Research Program shall be deemed
“Confidential Information” of Calithera. Notwithstanding the foregoing, there shall be excluded from the foregoing
definition of Confidential Information any of the foregoing that:

 

(a)               
either before or after the date of the disclosure to the receiving Party is lawfully disclosed to the receiving Party by
Third Parties without any violation of any obligation to the other Party; or

 

(b)              
either before or after the date of the disclosure to the receiving Party, becomes published or generally known to the public
through no fault or omission on the part of the receiving Party or its Agents; or

 

(c)               
is independently developed by or for the receiving Party without reference to or reliance upon the Confidential Information
as demonstrated by contemporaneous written records of the receiving Party; or

 

(d)              
is required to be disclosed by the receiving Party to comply with applicable Laws, to defend or prosecute litigation or
to comply with governmental regulations or the regulations or requirements of any stock exchange or securities commission, provided
that the receiving Party promptly provides prior notice of such disclosure to the other Party and uses reasonable efforts to
avoid or minimize the degree of such disclosure.

 

9.3             
Publication Rights.

 

(a)               
High Point shall not, and shall cause its controlled (as such word is defined in Section 1.2) Affiliates and their respective
employees, consultants, contractors, licensees and agents not to, publish or publicly present any results of any preclinical or
clinical studies with respect to any Program Molecule or Licensed Product without Calithera’s prior written consent, not
to be unreasonably withheld, conditioned or delayed. Calithera recognizes the importance of each Party’s ability to make
publications and in the spirit of scientific advancement, in the event High Point wishes to publish or publicly present such results,
High Point shall submit the proposed publication to the Development Forum sufficiently in advance of the proposed publication date
to allow Calithera to review and comment on the draft. Calithera shall advise the Development Forum as to the timing of the proposed
comments within thirty (30) days of submission to the Development Forum.

 

    	32

    	 

    

(b)              
During the Research Term, Calithera shall provide to High Point the opportunity to review any proposed abstracts, manuscripts
or summaries of presentations that cover any Program Molecule or Licensed Product as early as reasonably practicable following
Calithera’s publication of such proposed abstract, manuscript or summary for publication or presentation.

 

9.4             
Restrictions on Material Non-Public Information. Each Party acknowledges that it is aware that the United States
securities laws prohibit certain Persons who have received material, non-public information with respect to a public company from
purchasing or selling securities of that public company and from communicating such information to any other Person under circumstances
in which it is reasonably foreseeable that such Person is likely to purchase or sell such securities. Each Party acknowledges that
it is familiar with the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder
(collectively, the “1934 Act”); and agrees that it will neither use, nor cause or permit any person to use,
any Confidential Information in contravention of the 1934 Act, including Rule l0b-5 and Rule 14e-3 thereunder, or other applicable
securities laws.

 

Article
X

REPRESENTATIONS, WARRANTIES AND COVENANTS

 

10.1         
High Point’s Representations. High Point hereby represents and warrants as of the Effective Date as follows:

 

(a)               
High Point has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder.
The execution, delivery and performance of this Agreement has been duly and validly authorized and approved by proper corporate
action on the part of High Point. High Point has taken all other action required by Law, its certificate of incorporation or by-laws
or any agreement to which it is a party or by which it or its assets are bound, to authorize such execution, delivery and (subject
to obtaining all necessary governmental approvals with respect to the continued Development of Licensed Products) performance.
Assuming due authorization, execution and delivery on the part of Calithera, this Agreement constitutes a legal, valid and binding
obligation of High Point, enforceable against High Point in accordance with its terms.

 

    	33

    	 

    

(b)              
The execution and delivery of this Agreement by High Point and the performance by High Point, or its Affiliates or sublicensees,
contemplated hereunder will not violate (subject to obtaining all necessary governmental approvals with respect to High Point’s
obligations under the Research Program) any United States Law or, to High Point’s knowledge, any Law of any Governmental
Authority outside the United States.

 

(c)               
Neither the execution and delivery of this Agreement nor the performance hereof by High Point, or its Affiliates or sublicensees,
requires High Point, or its Affiliates or sublicensees, to obtain any permit, authorization or consent from any Governmental Authority
(subject to obtaining all necessary governmental approvals with respect to the continued Development of Licensed Products) or from
any other Person, and such execution, delivery and performance by High Point, or its Affiliates or sublicensees, will not result
in the breach of or give rise to any termination of, rescission, renegotiation or acceleration under or trigger any other rights
under any agreement or contract to which High Point, or its Affiliates or sublicensees, as applicable, may be a party that relates
to the High Point Patent Rights or the High Point Know-How, except any that would not, individually or in the aggregate, reasonably
be expected to adversely affect Calithera’s rights under this Agreement or the ability of High Point, or its Affiliates or
sublicensees, to perform its or their respective obligations under this Agreement.

 

(d)              
To High Point’s knowledge, no Third Party is infringing any of the High Point Patent Rights. To the knowledge of High
Point, the issued patents encompassed within High Point Patent Rights are valid and enforceable patents and no Third Party has
challenged the validity or enforceability of such patents (including by way of example through the institution or written threat
of institution of interference, nullity, revocation or similar invalidity proceedings before the United States Patent and Trademark
Office or any equivalent foreign entity).

 

(e)               
High Point Controls the High Point Patent Rights identified on Schedule 1.37. None of High Point’s controlled
(as such term is defined in Section 1.2) Affiliates own or Control any intellectual property related to Hexokinase Inhibitors.
No other Person has any right, interest or claim in or to, and High Point has not entered into any agreement granting any right,
interest or claim in or to, the High Point Patent Rights or High Point Know-How, including any lien, encumbrance, charge, security
interest, mortgage or other similar restriction; provided, however, that High Point makes no representation or warranty
as to whether any other Person has independently developed rights to scientific or technical information or related know-how or
trade secrets. High Point has entered into assignment agreements with all inventors of the High Point Intellectual Property owned
by High Point and, to High Point’s knowledge, all assignments to High Point of ownership rights relating to the High Point
Patent Rights owned by High Point are valid and enforceable.

 

(f)               
Schedule 1.37 is a complete and correct list of all High Point Patent Rights in the Territory owned by or licensed
to High Point as of the Effective Date.

 

    	34

    	 

    

(g)              
There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation
of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to High Point’s knowledge, threatened,
against High Point in connection with any High Point Patent Rights, High Point Know-How or against or relating to the transactions
contemplated by this Agreement.

 

(h)              
The information relating to High Point’s Hexokinase program that was provided by High Point to Calithera prior to
the Effective Date is, to High Point’s knowledge, true and correct in all material respects.

 

10.2         
Calithera’s Representations. Calithera hereby represents and warrants as of the Effective Date as follows:

 

(a)               
Calithera has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder.
The execution, delivery and performance of this Agreement has been duly and validly authorized and approved by proper corporate
action on the part of Calithera. Calithera has taken all other action required by Law, its certificate of incorporation or by-laws
or any agreement to which it is a party or by which it or its assets are bound to authorize such execution, delivery and (subject
to obtaining all necessary governmental approvals with respect to the Development, Manufacture and Commercialization of Program
Molecules and Licensed Products) performance. Assuming due authorization, execution and delivery on the part of High Point, this
Agreement constitutes a legal, valid and binding obligation of Calithera, enforceable against Calithera in accordance with its
terms.

 

(b)              
The execution and delivery of this Agreement by Calithera and the performance by Calithera contemplated hereunder will not
violate (subject to obtaining all necessary governmental approvals with respect to the continued Development, Manufacture and Commercialization
of Program Molecules and Licensed Products) any United States Law or, to Calithera’s knowledge, any Law of any Governmental
Authority outside the United States.

 

(c)               
There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation
of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Calithera, threatened
against Calithera in connection with or relating to the transactions contemplated by this Agreement.

 

(d)              
Neither the execution and delivery of this Agreement nor the performance hereof by Calithera requires Calithera to obtain
any permit, authorization or consent from any Governmental Authority (subject to obtaining all necessary governmental approvals
with respect to the continued Development, Manufacture and Commercialization of Program Molecules and Licensed Products) or from
any other Person, and such execution, delivery and performance by Calithera will not result in the breach of or give rise to any
termination of, rescission, renegotiation or acceleration under or trigger any other rights under any agreement or contract to
which Calithera may be a party that relates to the Licensed Products, Calithera Patent Rights or Calithera Know-How, except any
that would not, individually or in the aggregate, reasonably be expected to adversely affect High Point’s rights under this
Agreement or the ability of Calithera to perform its obligations under this Agreement.

 

    	35

    	 

    

(e)               
The information relating to Calithera’s plans for pursuing a Hexokinase program that was provided by Calithera to
High Point prior to the Effective Date is, to Calithera’s knowledge, true and correct in all material respects.

 

10.3         
Mutual Covenant. Each Party shall conduct, and shall use reasonable efforts to cause its contractors and consultants
to conduct, all of its activities contemplated under this Agreement in accordance with the Act, any similar foreign Law, and all
applicable Laws of the country in which such activities are conducted.

 

10.4         
No Warranty. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY HERETO MAKES ANY REPRESENTATION
AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. IN PARTICULAR, BUT WITHOUT LIMITATION, HIGH POINT MAKES NO REPRESENTATION
AND EXTENDS NO WARRANTY CONCERNING WHETHER ANY PROGRAM MOLECULE IS FIT FOR ANY PARTICULAR PURPOSE OR SAFE FOR USE IN HUMANS.

 

Article
XI

INDEMNIFICATION

 

11.1         
Indemnification in Favor of High Point. Calithera shall indemnify, defend and hold harmless the High Point Parties
(as hereinafter defined) from and against any and all Losses incurred, suffered or sustained by any of the High Point Parties or
to which any of the High Point Parties becomes subject, arising out of, relating to or resulting from any Third Party claim, action,
suit, proceeding, liability or obligation (collectively, “Third Party Claims”) arising out of, relating to or
resulting from:

 

(a)               
any misrepresentation or breach of any representation, warranty, covenant or agreement made by Calithera in this Agreement;
or

 

(b)              
the Development, Manufacture, use or Commercialization of a Program Molecule or Licensed Product by Calithera, its Affiliates
or Sublicensees, including all Third Party Claims involving (A) death or bodily injury caused or allegedly caused by the use of
a Program Molecule or Licensed Product, and even if a Program Molecule or Licensed Product is altered for use for a purpose not
intended or (B) any actual or alleged infringement of any trademark, Patent Right or other intellectual property right, or misappropriation
of any trade secret, of any Third Party; or

 

(c)               
the gross negligence or willful misconduct of any of the Calithera Parties (as hereinafter defined) in connection with Calithera’s
performance of this Agreement.

 

    	36

    	 

    

For purposes of this ARTICLE XI, “High Point Parties”
means High Point, its Affiliates and their respective licensors, agents, directors, officers, employees and shareholders.

 

The indemnification obligations set forth in this Section 11.1
shall not apply to the extent that any Loss is the result of a breach of this Agreement by High Point or, with respect to any indemnitee,
the gross negligence or willful misconduct of such indemnitee.

 

11.2         
Indemnification in Favor of Calithera. High Point shall indemnify, defend and hold harmless the Calithera Parties
from and against any and all Losses incurred, suffered or sustained by any of the Calithera Parties or to which any of the Calithera
Parties becomes subject, arising out of, relating to or resulting from any Third Party Claim arising out of, relating to or resulting
from:

 

(a)               
any misrepresentation or breach of any representation, warranty, covenant or agreement made by High Point in this Agreement;
or

 

(b)              
the gross negligence or willful misconduct of any of the High Point Parties in connection with High Point’s performance
of its obligations under this Agreement.

 

For purposes of this ARTICLE XI, “Calithera Parties”
means Calithera, its Affiliates and their respective agents, directors, officers, employees and shareholders.

 

The indemnification obligations set forth in this Section 11.2
shall not apply to the extent that any Loss is the result of a breach of this Agreement by Calithera or, with respect to any indemnitee,
the gross negligence or willful misconduct of such indemnitee.

 

11.3         
General Indemnification Procedures.

 

(a)               
A Person seeking indemnification pursuant to this ARTICLE XI (an “Indemnified Party”) shall give prompt
notice to the Party from whom such indemnification is sought (the “Indemnifying Party”) of the commencement
or assertion of any Third Party Claim (which in no event includes any claim by any Calithera Party or any High Point Party) in
respect of which indemnity may be sought hereunder, shall give the Indemnifying Party such information with respect to any indemnified
matter as the Indemnifying Party may reasonably request, and shall not make any admission concerning any Third Party Claim, unless
such admission is required by applicable Law or legal process, including in response to questions presented in depositions or interrogatories.
Any admission made by the Indemnified Party or the failure to give such notice shall relieve the Indemnifying Party of any liability
hereunder only to the extent that the ability of the Indemnifying Party to defend such Third Party Claim is prejudiced thereby
(and no admission required by applicable Law or legal process shall be deemed to result in prejudice). The Indemnifying Party shall
assume and conduct the defense of such Third Party Claim, with counsel selected by the Indemnifying Party and reasonably acceptable
to the Indemnified Party. Subject to the initial and continuing satisfaction of the terms and conditions of this ARTICLE XI, the
Indemnifying Party shall have full control of such Third Party Claim, including settlement negotiations and any legal proceedings.
If the Indemnifying Party does not assume the defense of such Third Party Claim in accordance with this Section 11.3, the Indemnified
Party may defend the Third Party Claim. If both Parties are Indemnifying Parties with respect to the same Third Party Claim, the
Parties shall determine by mutual agreement, within twenty (20) days following their receipt of notice of commencement or assertion
of such Third Party Claim (or such lesser period of time as may be required to respond properly to such claim), which Party shall
assume the lead role in the defense thereof. Should the Indemnifying Parties be unable to mutually agree on which of them shall
assume the lead role in the defense of such Third Party Claim, both Indemnifying Parties shall be entitled to participate in such
defense through counsel of their respective choosing.

 

    	37

    	 

    

(b)              
Any Indemnified Party or Indemnifying Party not managing the defense of a Third Party Claim shall have the right to participate
in (but not control), at its own expense (subject to the immediately succeeding sentence), the defense. The Indemnifying Party
managing the defense shall not be liable for any litigation cost or expense incurred, without its consent, by the Indemnified Party
(or an Indemnifying Party not managing the defense) where the action or proceeding is under the control of such Indemnifying Party;
provided, however, that if the Indemnifying Party managing the defense fails to take reasonable steps necessary to
defend such Third Party Claim, the Indemnified Party may assume its own defense, and the Indemnifying Party managing the defense
will be liable for all reasonable costs or expenses paid or incurred in connection therewith.

 

(c)               
The Indemnifying Party shall not consent to a settlement of, or the entry of any judgment against an Indemnified Party arising
from any such Third Party Claim to the extent such Third Party Claim involves equitable or other non-monetary relief from the Indemnified
Party. No Party shall, without the prior written consent of the other Party or the Indemnified Party, enter into any compromise
or settlement that commits the other Party or the Indemnified Party to take, or to forbear to take, any action.

 

(d)              
The Parties shall cooperate in the defense or prosecution of any Third Party Claim and shall furnish such records, information
and testimony, and attend such conferences, discovery proceedings, hearings, trials and appeals, as may be reasonably requested
in connection therewith.

 

(e)               
Any indemnification hereunder shall be made net of any insurance proceeds actually recovered by the Indemnified Party from
unaffiliated Third Parties; provided, however, that if, following the payment to the Indemnified Party of any amount
under this ARTICLE XI, such Indemnified Party recovers any such insurance proceeds in respect of the claim for which such indemnification
payment was made, the Indemnified Party shall promptly pay an amount equal to the amount of such proceeds (but not exceeding the
amount of such net indemnification payment) to the Indemnifying Party.

 

(f)               
The Parties agree and acknowledge that the provisions of this ARTICLE XI represent the Indemnified Party’s exclusive
recourse with respect to any Losses for which indemnification is provided to the Indemnified Party under this ARTICLE XI.

 

    	38

    	 

    

Article
XII

TERM AND TERMINATION

 

12.1         
Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless
earlier terminated as provided in this ARTICLE XII, shall continue in full force and effect, on a country-by-country and Licensed
Product-by-Licensed Product basis until there is no remaining royalty obligation in such country with respect to such Licensed
Product, at which time this Agreement shall expire in its entirety with respect to such Licensed Product in such country. The Term
shall expire on the date the Agreement has expired with respect to all Licensed Products in all countries in the Territory.

 

12.2         
Termination for Convenience. Calithera shall have the right to terminate this Agreement or the Research Program,
at any time and for any reason, upon ninety (90) days’ prior written notice to High Point. If Calithera terminates this Agreement
under this Section 12.2, then the provisions of Section 12.5 shall apply.

 

12.3         
Termination for Breach. In the event of a material breach of this Agreement by a Party, Calithera or HPP, as applicable,
may give the Party in default notice requiring it to cure such default. If such material breach is not cured within [***] days
after receipt of such notice, within [***] days in the case of a payment breach, or within [***] days in the case of a breach of
diligence obligations as set forth in ARTICLE VI, Calithera or HPP, as applicable, shall be entitled (without prejudice to any
of its other rights conferred on it by this Agreement or under applicable Law) to terminate this Agreement by giving written notice
to the defaulting Party, with such termination to take effect immediately. The right of Calithera or HPP to terminate this Agreement
as set forth in this Section 12.3 shall not be affected in any way by its waiver of, or failure to take action with respect to,
any previous default. If HPP terminates this Agreement under this Section 12.3, then the consequences set forth in Section 12.5
shall apply. In the event that a Party is notified by Calithera or HPP, as applicable, under this Section 12.3 that such Party
(as applicable, the “Defaulting Party”) has materially breached this Agreement, and such breach was caused by
a sublicensee of the Defaulting Party, and such breach is by its nature curable, then the Defaulting Party shall have an additional
[***] days after the applicable cure period set forth in the second sentence of this Section 12.3 to cure such breach.

 

12.4         
Termination for Insolvency. This Agreement may be terminated by Calithera or HPP upon written notice to the other
if (a) the other Party (HPP or Calithera, respectively) shall make an assignment for the benefit of its creditors, file a petition
in bankruptcy, petition or apply to any tribunal for the appointment of a custodian, receiver or trustee for it or a substantial
part of its assets, or shall commence any proceeding under any bankruptcy, reorganization, readjustment of debt, dissolution or
liquidation law or statute of any jurisdiction, whether now or hereafter in effect; or (b) if there shall have been filed against
HPP or Calithera, respectively, any such bona fide petition or application, or any such proceeding shall have been commenced
against it, in which an order for relief is entered or that remains undismissed or unstayed for a period of [***] days or more;
or (c) if HPP or Calithera, respectively, by any act or omission shall indicate its consent to, approval of or acquiescence in
any such petition, application or proceeding or order for relief or the appointment of a custodian, receiver or trustee for it
or any substantial part of its assets, or shall suffer any such custodianship, receivership or trusteeship to continue undischarged
or unstayed for a period of [***] days or more. Termination shall be effective upon the date specified in such notice. If HPP terminates
this Agreement under this Section 12.4, then the provisions of Section 12.5 shall apply. If Calithera terminates this Agreement
under this Section 12.4, then the provisions of Section 12.6 shall apply.

 

    	39

    	 

    

12.5         
Consequences of Certain Terminations by the Parties. If this Agreement is terminated by Calithera under Section 12.2,
or by HPP under Section 12.3 or 12.4, then the license granted to Calithera in Section 2.1 shall terminate, and for a period of
[***] days after such termination, HPP shall have the exclusive right to elect, via written notice(s) to Calithera, to acquire,
license or gain access to all or a portion of the following as set forth in such notice(s). To the extent reasonably accessible
and without additional unreimbursed out-of-pocket cost to Calithera, for a reasonable period of time, not to exceed [***] but no
less than [***] after HPP’s election under this Section 12.5, Calithera shall provide such elected items and perform such
elected activities, subject to applicable Third Party agreements or legal obligations, including to clinical sites, patients, institutional
review boards, or Third Party vendors, as to whom Calithera shall provide reasonable letters of introduction as requested by HPP;
provided that Calithera may keep a copy of all documents for its records or a sample of any materials:

 

(a)               
Regulatory Matters. Ownership of all regulatory filings and Regulatory Approvals relating to the Program Molecules
and the Licensed Products, and copies of related material correspondence with Regulatory Authorities, as maintained as of the effective
date of termination, and performance by Calithera of the activities set forth on Schedule 12.5(a), subject to reimbursement
of reasonable internal costs of Calithera for such transfer, with the reasonable internal rate for Calithera employees’ time
not to exceed [***] per hour; provided that the first [***] hours of Calithera employees’ time devoted to activities
under this Section 12.5(a) shall not be subject to reimbursement;

 

(b)              
Pre-clinical and Clinical Matters. All pre-clinical and clinical data, including pharmacology and biology data, specifically
relating to Program Molecules and Licensed Products, but excluding any comparison data or business analysis, and performance by
Calithera of the activities set forth on Schedule 12.5(b) in each case to the extent in Calithera’s possession or
control or, if not in Calithera’s possession or control, to the extent Calithera’s standard operating procedures provide
for their preparation;

 

(c)               
High Point Documents and Materials. All documents and materials received from High Point;

 

    	40

    	 

    

(d)              
Manufacturing Matters. Subject to (x) Calithera Patent Rights (which shall be licensed pursuant to Section 12.5(e)
below) and (y) Calithera’s proprietary information and systems developed independently of this Agreement, subject to applicable
agreements or legal obligations including to clinical sites, patients, institutional review boards, or third-party vendors, provided
that Calithera may keep a copy of all documents for its records or a sample of any materials:

 

(i)                
assignment of each manufacturing agreement for Program Molecules or Licensed Products to HPP (or, where such agreement is
not specific to Program Molecules or Licensed Products, the benefit thereof);

 

(ii)              
cooperation with HPP in reasonable respects to transfer manufacturing documents and materials which are used (at the time
of the termination) by Calithera exclusively in the Manufacture of Program Molecules and Licensed Products to the extent such manufacturing
documents and materials are not obtained by HPP pursuant to paragraph (i) above;

 

(iii)            
cooperation with HPP in reasonable respects to transfer manufacturing technologies Controlled by Calithera which are used
(at the time of the termination) exclusively in the Manufacture of Program Molecules and Licensed Products to the extent such manufacturing
documents and materials are not obtained by HPP pursuant to paragraphs (i) and (ii) above, provided that HPP shall pay Calithera’s
reasonable internal rates and expenses to provide such requested assistance, with the reasonable internal rate for Calithera employees’
time not to exceed [***] per hour; provided that the first [***] hours of Calithera employees’ time devoted to activities
under this Section 12.5(d)(iii) shall not be subject to reimbursement;

 

(iv)            
Calithera’s then existing inventory of Program Molecules and Licensed Products to HPP, at [***], but only if the following
conditions have been met: (A) such Program Molecules and Licensed Products meet the applicable release specifications; (B) Calithera
does not reasonably believe the continued use of such Program Molecules and Licensed Products cause safety concerns; and (C) HPP
shall not place into commerce products marked with Calithera’s House Marks as defined in Section 12.5(f) below;

 

(v)              
in the event this Agreement is terminated after Initiation of a Phase III Clinical Trial of a Licensed Product, use of Commercially
Reasonable Efforts using Calithera’s then existing manufacturing facilities and equipment to Manufacture and supply HPP’s
requirements of such Licensed Product for a period of no longer than [***] after the effective date of termination, at [***], provided
that HPP shall not place into commerce products marked with Calithera’s House Marks as defined in Section 12.5(f) below;

 

    	41

    	 

    

(e)               
License Grant. At HPP’s option, to be exercised no later than [***] days after the effective date of termination:

 

(i)                
Effective upon the date of termination by Calithera under Section 12.2, or by HPP under Section 12.3 or 12.4, Calithera
shall and hereby does grant to HPP a non-exclusive, fully paid-up, non-royalty-bearing, irrevocable, perpetual license, with the
right to grant sublicenses under multiple tiers, under the Calithera Know-How solely to the extent required to make, have made,
use, sell, offer for sale and import the Program Molecules and the Licensed Products in the Territory; provided that with
respect to any Calithera Know-How that Calithera acquired from another Person (by license or otherwise), Calithera shall only be
required to grant to HPP a license to such Calithera Know-How to the extent permitted under its agreement with such Person, and,
after the effective date of termination, HPP shall pay Calithera or such Person any payment that becomes due to such Person arising
from the activities of HPP, its Affiliates or sublicensees relating to the Program Molecules and Licensed Products; provided
further that HPP shall execute mutually acceptable documentation to effectuate such agreement;

 

(ii)              
Effective upon the date of termination by Calithera under Section 12.2, or by HPP under Section 12.3 or 12.4, Calithera
shall and hereby does grant to HPP an exclusive, royalty-bearing, irrevocable, perpetual license, with the right to grant sublicenses
under multiple tiers (A) under the Program Patent Rights solely to the extent required to make, have made, use, sell, offer for
sale and import Program Molecules and Licensed Products in the Territory, and (B) under the Calithera Patent Rights (that are not
Program Patent Rights and that are actually used in the discovery, Development, Commercialization or Manufacture of any Program
Molecule or Licensed Product) solely to the extent required to make, have made, use, sell, offer for sale and import the Program
Molecules and the Licensed Products in the Territory. In consideration of such license, HPP shall pay to Calithera following the
effective date of termination a royalty equal to (y) [***] of the royalties set forth in Section 7.6 of net sales of such Licensed
Products, if such termination [***] or (x) [***] of the royalties set forth in Section 7.6 of net sales of such Licensed Products,
if such termination [***] (in each case with (1) such net sales being determined by applying the definitions of Net Sales mutatis
mutandis to any sales of such Licensed Products by HPP, its Affiliates or sublicensees, and (2) the duration of such royalty
payments being, on a country-by-country basis, the period commencing on the first commercial sale by HPP, its Affiliates or sublicensees
in such country and ending on the date on which the manufacture, use, sale, offer for sale or importation of such Program Molecules
or such Licensed Products in such country ceases to be Covered by a valid claim of the Calithera Patent Rights or Program Patent
Rights (with valid claim to be determined by applying the definition of Valid Claim to Calithera Patent Rights or Program Patent
Rights) in such country; provided that, with respect to any Calithera Patent Rights that Calithera acquired from another
Person (by license or otherwise), Calithera shall only be required to grant to HPP a license to such Calithera Patent Rights to
the extent permitted under its agreement with such Person, and, after the effective date of termination, HPP shall pay Calithera
or such Person any payment that becomes due to such Person arising from the activities of HPP, its Affiliates or sublicensees relating
to such Program Molecules or such Licensed Products; provided further that HPP shall execute mutually acceptable documentation
to effectuate such agreement;

 

    	42

    	 

    

(iii)            
With respect to enforcement of any Calithera Patent Rights or Program Patent Rights (including Joint Patents) licensed to
HPP pursuant to Section 12.5(e)(ii) above, HPP shall have the same rights as Calithera has with respect to High Point Patent Rights
pursuant to Section 8.3, but only with respect to infringement that involves the making, using, selling, offering for sale
and importing of a product by a Third Party that contains a Hexokinase Inhibitor in the Field in the Territory;

 

(iv)            
If Calithera determines to abandon in all or any portion of the Territory any Calithera Patent Right (other than a Joint
Patent) licensed to HPP pursuant to Section 12.5(e)(ii) (the “Abandoned Calithera Patent”), Calithera shall
notify HPP of such determination, no later than thirty (30) days before any deadline for further action to avoid abandonment.

 

(A)            
In the case of any pending application for an Abandoned Calithera Patent, if HPP wishes to continue to prosecute such Abandoned
Calithera Patent in such Territory, Calithera may elect to continue to prosecute such Abandoned Calithera Patent in such Territory
or allow HPP to have the sole right, but not the obligation, to continue to prosecute such Abandoned Calithera Patent [***]. HPP
may only elect to continue to prosecute such Abandoned Calithera Patent that exclusively relates to Program Molecules or Licensed
Products. To the extent permitted by applicable Laws, a patent application that relates to, but does not exclusively relate to,
the Program Molecules or Licensed Products, will be split such that the claims of the patent application only recite subject matter
exclusively related to Program Molecules or Licensed Products. Divisionals or other patent applications that do not specifically
relate to Program Molecules or Licensed Products shall be excluded from the Calithera Patent Rights licensed to HPP pursuant to
Section 12.5(e)(ii).

 

(B)             
In the case of any issued Abandoned Calithera Patent, if HPP wishes to continue to maintain such Abandoned Calithera Patent
in such Territory, Calithera may elect to continue to maintain such Abandoned Calithera Patent in such Territory or allow HPP to
have the sole right, but not the obligation, to continue to maintain the Abandoned Calithera Patent [***].

 

(C)             
If either Party elects to continue to prosecute and maintain any Abandoned Calithera Patent, the other Party shall reasonably
cooperate to transfer such prosecution and maintenance of such Abandoned Calithera Patent;

 

(v)              
Calithera shall have the right under Section 8.2(c) to regain control of prosecution and maintenance of any Abandoned Joint
Patent licensed to HPP at any time, subject to [***] and [***] for such Abandoned Calithera Patent. If either Party elects to maintain
any Abandoned Calithera Patent, the other Party shall reasonably cooperate to transfer such maintenance and prosecution thereof;

 

(vi)            
The roles of HPP and Calithera with respect to patent term extensions under Section 8.5 shall be reversed;

 

    	43

    	 

    

(vii)          
If Calithera becomes aware of any certification filed pursuant to 21 U.S. C. § 355(b)(2)(A) or 355(j)(2)(A)(vii)(IV)
(or any amendment or successor statute thereto) claiming that any Calithera Patent Rights (including an Abandoned Calithera Patent
and Joint Patents, including an Abandoned Joint Patent) licensed to HPP pursuant to Section 12.5(e)(ii) are invalid or otherwise
unenforceable, or that infringement will not arise from the manufacture, use, import or sale of a product by a Third Party, Calithera
shall promptly notify HPP in writing within five (5) Business Days after its receipt thereof;

 

(f)               
Assignment of Trademark. Calithera agrees to and hereby assigns to HPP of all of Calithera’s right, title and
interest in any trademark used solely in connection with the Licensed Products, provided that said assignment shall not
include any trademark relating to the name ‘Calithera’ or the business names or trade names of any of Calithera’s
Affiliates or Sublicensees (“House Marks”).

 

(g)              
Limitation on Remedy. In the event this Agreement is terminated by Calithera under Section 12.2, or by High Point
under Section 12.3 or 12.4, and HPP elects to obtain any of the items under Section 12.5 then the fair market value of such items
obtained by HPP shall be deducted from any damages to which High Point may otherwise be entitled hereunder in connection with such
termination.

 

12.6         
Payment of Balance of Quarterly Research Fees.

 

(a)               
If Calithera terminates this Agreement or the Research Program during the Research Program Term pursuant to Section 12.2,
then HPP shall retain all Quarterly Research Fees paid by Calithera under Section 7.2 prior to the effective date of such termination,
and [***] the effective date of such termination, which Quarterly Research Fee shall be [***] the Research Program [***] (or [***]
the Research Program) [***] the date of termination and shall be [***] Quarterly Research Fee [***].

 

(b)              
If Calithera terminates this Agreement or the Research Program during the Research Program Term pursuant to Section 12.3
or 12.4, then HPP shall retain all Quarterly Research Fees paid by Calithera under Section 7.2 prior to the effective date of such
termination

 

(c)               
For purposes of clarity, a termination of the Research Program shall not constitute a termination of the Agreement, unless
explicitly stated in such termination notice.

 

12.7         
Unblock License. Upon termination or expiration of this Agreement (other than a termination by High Point pursuant
to Section 12.3 or 12.4), High Point shall and hereby does grant to Calithera a perpetual, irrevocable, fully paid-up, royalty-free,
worldwide, non-exclusive license, with the right to grant sublicenses under multiple tiers, under the High Point Sole Inventions
conceived under the Research Program, provided that if HPP exercises its option to obtain the license set forth in Section
12.5(e)(ii), Calithera shall have no rights under the license granted under this Section 12.7 to make, have made, use, sell, offer
for sale or import Program Molecules or Licensed Products in the Field in the Territory.

 

    	44

    	 

    

12.8         
Effect of Termination and Expiration; Accrued Rights and Obligations. Termination of this Agreement for any reason
shall not release either Party from any liability that, at the time of such termination, has already accrued or that is attributable
to a period prior to such termination (including payment obligations accrued prior to the effective date of termination pursuant
to Sections 7.4, 7.5 or 7.6) nor preclude either Party from pursuing any right or remedy it may have hereunder or at Law or in
equity with respect to any breach of this Agreement. It is understood and agreed that monetary damages may not be a sufficient
remedy for any breach of this Agreement and that the non-breaching Party may be entitled to seek injunctive relief as a remedy
for any such breach. HPP shall have no obligation to repay any Quarterly Research Fee paid pursuant to Section 7.2 following any
termination of this Agreement.

 

12.9         
Survival. The rights and obligations set forth in this Agreement shall extend beyond the Term or termination of this
Agreement only to the extent expressly provided for in this Agreement or to the extent required to give effect to a termination
of this Agreement or the consequences of a termination of this Agreement as expressly provided for in this Agreement. Without limiting
the generality of the foregoing, it is agreed that the provisions of ARTICLE I, Sections 2.3, 7.6(b) (with respect to the fully
paid-up license granted therein), 7.7, 7.8, 7.9, 7.10, 7.11, 7.12, 8.1, 8.2(a), 8.2(c) (and with respect to Calithera Patent Rights,
Joint Patents and Joint Inventions, only, and subject to Sections 8.9(b) and 12.5(e), Sections 8.2(d), 8.3, 8.4, 8.7 and 8.8),
8.5 (subject to Section 12.5(e)(vi)), 8.9(b), 9.1, 9.2, 9.4, 11.1, 11.2, 11.3, 12.5, 12.6, 12.7, 12.8, 12.9, 13.1, 13.2, 13.3,
13.4, 13.5, 13.6, 13.7, 13.8, 13.9, 13.10, 13.11, 13.12, 13.13, 13.14, 13.15, 13.16 and 13.17 shall survive expiration or termination
of this Agreement for any reason.

 

Article
XIII

MISCELLANEOUS

 

13.1         
Governing Law. This Agreement shall be governed by and interpreted in accordance with the internal laws of the State
of Delaware, without regard to its conflicts of laws rules.

 

13.2         
Jurisdiction. Each Party (a) irrevocably submits to the exclusive jurisdiction in any state or federal court sitting
in Wilmington, Delaware (collectively, the “Courts”), for purposes of any action, suit or other proceeding arising
out of this Agreement, and (b) agrees not to raise any objection at any time to the laying or maintaining of the venue of any such
action, suit or proceeding in any of the Courts, irrevocably waives any claim that such action, suit or other proceeding has been
brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action, suit or other
proceeding, that such Court does not have any jurisdiction over such Party. Either Party may serve any process required by such
Courts by way of notice under this Agreement pursuant to Section 13.4.

 

    	45

    	 

    

13.3         
Waiver. Waiver by a Party of a breach hereunder by the other Party shall not be construed as a waiver of any succeeding
breach of the same or any other provision. No delay or omission by a Party to exercise or avail itself of any right, power or privilege
that it has or may have hereunder shall operate as a waiver of any right, power or privilege by such Party. No waiver shall be
effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized
representative of the Party granting the waiver.

 

13.4         
Notices. All notices, instructions and other communications hereunder or in connection herewith shall be in writing,
shall be sent to the address specified in this Section 13.4 and shall be: (a) delivered personally; (b) sent by registered or certified
mail, return receipt requested, postage prepaid; (c) sent via a reputable nationwide overnight courier service; or (d) sent by
facsimile transmission. Any such notice, instruction or communication (except as provided expressly herein) shall be deemed to
have been delivered upon receipt if delivered by hand, three (3) Business Days after it is sent by registered or certified mail,
return receipt requested, postage prepaid, one (1) Business Day after it is sent via a reputable nationwide overnight courier service,
or when transmitted with electronic confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business
Day; otherwise, on the next Business Day following such transmission).

 

Notices to Calithera shall be addressed to:

 

Calithera Biosciences Inc.

343 Oyster Point Blvd #200

South San Francisco, CA 94080

Attention: Curtis Hecht

Vice President, Business and Corporate Development

Facsimile: (650) 588-5272

 

with a copy to:

 

Calithera Biosciences Inc.

343 Oyster Point Blvd #200

South San Francisco, CA 94080

Attention: Terri Davis

Associate Director, Intellectual Property and Legal Affairs

Facsimile: (650) 319-8093

 

and

 

Foley Hoag LLP

Seaport West

155 Seaport Boulevard

Boston, MA 02210-2600

Attention: Hemmie Chang

Facsimile: 617-832-7000

 

    	46

    	 

    

Notices to High Point shall be addressed to:

 

High Point Pharmaceuticals, LLC

4170 Mendenhall Oaks Parkway

High Point, NC 27265

Attention: President

Facsimile: 336-841-0310

 

with a copy to:

 

TransTech Pharma LLC

4170 Mendenhall Oaks Parkway

High Point, NC 27265

Attention: President

Facsimile: 336-841-0310

 

Either Party may change its address by giving
notice to the other Party in the manner provided above.

 

13.5         
Entire Agreement. This Agreement (including Schedules) contains the complete understanding of the Parties with respect
to the research, Development, Manufacture and Commercialization of Program Molecules and Licensed Products and supersedes all prior
understandings and writings relating to such subject matter. In particular, and without limitation, it supersedes and replaces
the Confidentiality Agreements and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged
between the Parties prior to the Effective Date.

 

13.6         
Headings. Headings in this Agreement are for convenience of reference only and shall not be considered in construing
this Agreement.

 

13.7         
Severability. If any provision of this Agreement is held unenforceable by a court or tribunal of competent jurisdiction
because it is invalid or conflicts with any Law of any relevant jurisdiction, the validity of the remaining provisions shall not
be affected. In such event, the Parties shall negotiate a substitute provision that, to the extent possible, accomplishes the original
business purpose.

 

13.8         
Registration and Filing of the Agreement. To the extent a Party determines in good faith that it is required by applicable
Law to publicly file, register or notify this Agreement with a Governmental Authority, including public filings pursuant to securities
Laws, it shall provide the proposed redacted form of the Agreement to the other Party a reasonable amount of time prior to filing
for the other Party to review such draft and propose changes to such proposed redactions. The Party making such filing, registration
or notification shall incorporate any proposed changes timely requested by the other Party, absent a substantial reason to the
contrary, and shall use commercially reasonable efforts to seek confidential treatment for any terms that the other Party timely
requests be kept confidential, to the extent such confidential treatment is reasonably available consistent with applicable Law.
Each Party shall be responsible for its own legal and other external costs in connection with any such filing, registration or
notification.

 

    	47

    	 

    

13.9         
Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred
by Calithera, HPP or TransTech (the “Assignor”) without the consent of the other Party; provided, however,
that an Assignor may, without such consent, assign this Agreement, in whole or in part: (i) to any of its Affiliates, provided
that the Assignor shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned or
transferred and such Affiliate has acknowledged and confirmed in writing that, effective as of such assignment or other transfer,
such Affiliate shall be bound by this Agreement as if it were a party to it as and to the identical extent applicable to the Assignor;
or (ii) to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this
Agreement relates, provided that such successor agrees in writing to be bound by the terms of this Agreement as if it were
the Assignor and to assume all obligations of the Assignor under this Agreement. Any purported assignment or transfer in violation
of this Section 13.9 shall be void. Notwithstanding the foregoing provisions of this Section 13.9, each Party acknowledges and
agrees that the other Party may satisfy any of its performance obligations under this Agreement through permitted sublicensees
in accordance with Section 2.1(b) or 2.2(b).

 

13.10     
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. Such counterparts may be exchanged by facsimile or PDF (provided
that each executed counterpart is transmitted in one complete transmission or electronic mail message). Where there is an exchange
of executed counterparts by facsimile or PDF, each Party shall be bound by the Agreement notwithstanding that original copies of
the Agreement may not be exchanged immediately. The Parties shall cooperate after execution of the Agreement and exchange by facsimile
or PDF to ensure that each Party obtains an original executed copy of this Agreement with reasonable promptness.

 

13.11     
Force Majeure. No Party shall be liable for failure of or delay in performing obligations set forth in this Agreement,
and no Party shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire,
flood, tornadoes, thunderstorms, earthquake, war, terrorism, riots, embargo, losses or shortages of power, labor stoppage, substance
or material shortages, damage to or loss of product in transit, events caused by reason of Laws of any Governmental Authority,
events caused by acts or omissions of a Third Party, or any other cause reasonably beyond the control of such Party.

 

13.12     
Press Releases and Other Disclosures. The Parties hereby each approve the forms of separate press releases set forth
in Schedule 13.12 hereto and will cooperate in the release thereof as soon as practicable after the Effective Date. The
Parties also recognize that each Party may from time to time desire to issue additional press releases and make other public statements
or disclosures regarding the subject matter of this Agreement. In such event, subject to Section 9.4, the Party desiring to issue
an additional press release or make a public statement or disclosure shall provide the other Party with a copy of the proposed
press release, statement or disclosure for review and approval in advance, which advance approval shall not be unreasonably withheld,
conditioned or delayed (except that neither Party shall have any obligation to disclose Confidential Information except to the
extent required or permitted pursuant to ARTICLE IX). No other public statement or disclosure concerning the existence or terms
of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written approval of
the other Party. Once any public statement or disclosure has been approved in accordance with this Section, then either Party may
appropriately communicate information contained in such permitted statement or disclosure. Notwithstanding the foregoing provisions
of this Section 13.12 or of ARTICLE IX, a Party may (a) disclose the existence and terms of the this Agreement where required,
as reasonably determined by the disclosing Party, by applicable Law, by applicable stock exchange regulation or by order or other
ruling of a competent court, (b) disclose the existence and terms of this Agreement under obligations of confidentiality to agents,
advisors, contractors, investors and sublicensees, and to potential agents, advisors, contractors, investors and sublicensees,
in connection with such Party’s activities hereunder and in connection with such Party’s financing activities and (c)
publicly announce any of the matters set forth in Schedule 13.12, provided that such announcements do not entail
disclosure of non-public technical or scientific information (which, for purposes of clarity, excludes clinical trial results)
and the announcing Party provides the other Party with a copy of the proposed text of such announcement sufficiently in advance
of the scheduled release or publication thereof to afford such other Party a reasonable opportunity to review and comment upon
the proposed text.

 

    	48

    	 

    

13.13     
Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by
any Third Party other than an indemnitee under ARTICLE XI. No such Third Party shall obtain any right under any provision of this
Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise)
against either Party.

 

13.14     
Relationship of the Parties. Each Party shall bear its own costs incurred in the performance of its obligations hereunder
without charge or expense to the other, except as expressly provided in this Agreement. Neither Party shall have any responsibility
for the hiring, termination or compensation of the other Party’s employees or for any employee compensation or benefits of
the other Party’s employees. No employee or representative of a Party shall have any authority to bind or obligate the other
Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on the other Party without
said other Party’s approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary,
the legal relationship under this Agreement of each Party to the other Party shall be that of independent contractor. Nothing in
this Agreement shall be construed to establish a relationship of partners or joint venturers between the Parties.

 

13.15     
Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party
agrees to cause its Affiliates to perform such obligations.

 

    	49

    	 

    

13.16     
Construction. Each Party acknowledges that it has been advised by counsel during the course of negotiation of this
Agreement, and, therefore, that this Agreement shall be interpreted without regard to any presumption or rule requiring construction
against the Party causing this Agreement to be drafted. Any reference in this Agreement to an Article, Section, subsection, paragraph,
clause or Schedule shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause or Schedule, of or
to, as the case may be, this Agreement. Except where the context otherwise requires, (a) wherever used, the use of any gender will
be applicable to all genders, (b) the word “or” is used in the inclusive sense (and/or), (c) any definition of or reference
to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein
or therein), (d) any reference to any Laws refers to such Laws as from time to time enacted, repealed or amended, (e) the words
“herein”, “hereof” and hereunder”, and words of similar import, refer to this Agreement in its entirety
and not to any particular provision hereof, (f) the words “include”, “includes” and “including”
shall be deemed to be followed by the phrase “but not limited to”, “without limitation” or words of similar
import, and (g) all dollar ($) amounts specified herein are United States dollar amounts.

 

13.17     
No Consequential or Punitive Damages. NEITHER PARTY WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL,
EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF
SUCH DAMAGES. NOTHING IN THIS SECTION 13.17 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER
PARTY UNDER THIS AGREEMENT WITH RESPECT TO THIRD PARTY CLAIMS, OR WITH RESPECT TO THE INFRINGEMENT OR MISAPPROPRIATION OF THE OTHER
PARTY’S INTELLECTUAL PROPERTY RIGHTS OR CONFIDENTIAL INFORMATION.

 

[Remainder of page intentionally left
blank.]

 

    	50

    	 

    

IN WITNESS WHEREOF, the Parties have signed
this Agreement as of the Effective Date.

 

	CALITHERA BIOSCIENCES INC.	 	HIGH POINT PHARMACEUTICALS, LLC	 
	By:	/s/ Susan Molineaux	 	By:	/s/ Stephen L.  Holcombe	 
	Name:	Susan Molineaux, Ph.D.	 	Name:	Stephen L.  Holcombe	 
	Title:	President & CEO	 	Title:	President & CFO	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	TRANSTECH PHARMA LLC	 
	 	 	 	By:	/s/ Stephen L.  Holcombe	 
	 	 	 	Name:	Stephen L.  Holcombe	 
	 	 	 	Title:	President & CFO	 

 

 

    	51

    	 

    

Schedule 1.33

 

Hexokinase Inhibitor Assay

 

[***]

 

    	52

    	 

    

Schedule 1.37

 

High Point Patent Rights

 

	File No.	Application No.	Filing Date	Assignee	Title	Status
	[***]	[***]	[***]	[***]	[***]	[***]

 

    	53

    	 

    

 

	File No.	Application No.	Filing Date	Assignee	Title	Status
	[***]	[***]	[***]	[***]	[***]	[***]

 

 

    	54

    	 

    

Schedule 1.66

 

Research Plan

 

[***]

 

    	55

    	 

    

[***]

 

    	56

    	 

    

[***]

 

    	57

    	 

    

Schedule 7.2

 

(a)

 

	Maximum Number of FTEs during Research Program Term	FTE Rate	Maximum Annual Payment by Calithera	Maximum Quarterly Payment by Calithera (Prorated for four (4) FTEs)
	Four (4)	$275,000	$1,100,000	$275,000

 

(b)

 

	Minimum Number of FTEs during Research Program Term	FTE Rate	Minimum Annual Payment by Calithera	Minimum Quarterly Payment by Calithera (Prorated for three (3) FTEs)
	[***]	$275,000	$[***]	$[***]

 

(c)

 

	 	Q1	Q2	Q3	Q4
	Minimum Fee (Prorated for [***] FTEs)	$[***]	$[***]	$[***]	$[***]
	Maximum Fee (Prorated for four (4) FTEs)	$275,000	$275,000	$275,000	$275,000

    	58

    	 

    

Schedule 7.10

 

HPP Wiring Instructions

 

	Account Name:	High Point Pharmaceuticals LLC
	Account Number:	[***]	 
	Routing Number:	[***] (for domestic transfers)
	SWIFT Code:	[***] (for international transfers)	

 

    	59

    	 

    

Schedule 12.5(a)

 

Transition of Regulatory Matters

 

[***]

 

    	60

    	 

    

Schedule 12.5(b)

 

Transition of Pre-Clinical and Clinical
Matters

 

[***]

 

    	61

    	 

    

[***]

 

    	62

    	 

    

[***]

 

    	63

    	 

    

[***]

 

    	64

    	 

    

[***]

 

    	65

    	 

    

[***]

 

    	66

    	 

    

Schedule 13.12

 

Press Releases

 

 

Calithera Biosciences Gains Exclusive, Worldwide License
to TransTech Pharma’s Hexokinase II Inhibitor Program

 

South San Francisco, Calif., March 05, 2015 --(GLOBE NEWSWIRE)--
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced
today an exclusive global license agreement with TransTech Pharma, a clinical stage pharmaceutical company, granting Calithera
exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors. Hexokinase
II is the first and rate-limiting enzyme in the pathway that enables cancer cells to convert glucose to energy and building blocks
that feed cancer cell growth. Under the terms of the agreement, Calithera will obtain exclusive, worldwide rights to TransTech’s
hexokinase II inhibitors for research, development and commercialization. TransTech will receive an upfront payment and will be
eligible to receive future development and commercialization milestones as well as royalties on sales of approved products.

 

“TransTech’s hexokinase II inhibitor program will
further expand Calithera’s portfolio of pre-clinical programs and solidify our leadership in the area of tumor metabolism
drug research and development as we are now able to target two essential nutrients that cancer cells rely on for growth and survival:
glutamine and glucose,” said Susan M. Molineaux, CEO, Calithera Biosciences. “We believe we can apply our expertise
to rapidly advance TransTech’s potent small-molecule hexokinase II inhibitors into the clinic to become our third potential
first-in-class therapy for cancer patients.”

 

About Tumor Metabolism and Hexokinase II Inhibitors

 

The field of tumor metabolism seeks to exploit the unique ways
in which cancer cells take up and utilize nutrients in order to grow and proliferate. Cancer cells have altered cellular metabolic
pathways to acquire and utilize these nutrients and redirect them to provide the necessary building blocks for growth. When these
metabolic pathways are blocked, cancer cells are essentially starved of critical nutrients and stop growing or die, whereas normal
cells are largely unaffected.

 

    	67

    	 

    

Most cancer cells have increased uptake of the sugar glucose
relative to surrounding normal cells. This phenomenon forms the basis for the widely used tumor imaging procedure known as 18F-2-deoxyglucose (FDG)/PET.
Tumors take up more FDG, a radioactive glucose analog, than the surrounding normal tissue and this differential can be visualized
with PET imaging. Not only do tumors take up more glucose, but they also utilize the nutrient in a unique way. Tumors convert glucose
into lactic acid in a process known as aerobic glycolysis or the “Warburg effect”, a route rarely utilized in normal
cells. This unique uptake and processing of glucose by tumors relative to normal tissue creates an opportunity to selectively target
tumors by cutting off their ability to use this fuel.

 

In many cancers, hexokinase II is over expressed and has been
linked to more aggressive and invasive tumors. Pre-clinical studies in mice have confirmed that the reduction of hexokinase II
activity through genetic deactivation (siRNA knockdown studies) results in a significant reduction of tumor growth. The hexokinase
inhibitors in-licensed from TransTech may provide an opportunity to inhibit the unique way cancer cells utilize glucose, and the
overall Warburg effect, which could result in new treatments for cancer.

 

About Calithera Biosciences

 

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology
targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, an orally bioavailable inhibitor of glutaminase,
is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in
South San Francisco. For more information about Calithera, please visit www.calithera.com.

 

About TransTech Pharma

 

TransTech Pharma, LLC is a privately held, clinical-stage pharmaceutical
company focused on the discovery and development of human therapeutics to fill unmet medical needs. The Company’s high-throughput
drug discovery platform, Translational Technology®, translates the functional modulation of human proteins into safe and effective
medicines. TransTech Pharma, LLC has a pipeline of small-molecule clinical and pre-clinical drug candidates for the treatment of
a wide range of human diseases, including central nervous system disorders, diabetes and metabolic disorders, inflammation and
oncology. For further company information, visit http://www.ttpharma.com

 

    	68

    	 

    

Forward-Looking Statements

 

This news release contains forward-looking statements by Calithera
that involve risks and uncertainties. These statements include those related to Calithera’s ability to rapidly advance TransTech’s
potent small-molecule hexokinase II inhibitors into the clinic; that hexokinase II inhibitors may have therapeutic potential in
the treatment of cancer; and the potential of tumor metabolism pathways to be transformational in the treatment of cancer. Actual
results may differ from Calithera’s expectations and important factors that could cause actual results to differ materially.
Calithera’s hexokinase II inhibitor program or other potential product candidates that Calithera develops may not progress
through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical
trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product
candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any
of the foregoing matters may have a negative effect on Calithera’s stock price. Additional information concerning these and
other risk factors affecting Calithera’s business can be found in Calithera’s Quarterly Report on Form 10-Q for the
period ended September 30, 2014 and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking
statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera
disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

 

SOURCE: Calithera Biosciences, Incorporated

 

CONTACT:

 

Jennifer McNealey

 

Calithera Biosciences, Inc.

 

ir@Calithera.com

 

650-870-1071

 

 

    	69

    	 

    

Schedule 13.12 (cont’d)

 

Press Releases

 

TransTech Pharma and Calithera Biosciences
Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program

 

High Point, NC, March 05, 2015 - TransTech Pharma, LLC today
announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and
commercialize TransTech’s portfolio of hexokinase II inhibitors. TransTech will receive an upfront payment and will be eligible
to receive future development and commercialization milestones as well as royalties on sales of approved products.

 

Hexokinase II is the first enzyme in the pathway that enables
cancer cells to convert glucose to energy and building blocks required for cancer cell growth. The Warburg effect describes the
particular reliance of cancer cells on glycolysis for energy and tumor cell survival. FDG-PET imaging of cancer and diagnosis in
the clinic exploits the Warburg effect by detection of increased uptake of a glucose analogue by cancer cells. Increased glycolysis
has been posited to be an essential part of carcinogenesis, conferring a significant growth advantage as well as promoting typical
tumor progression making it a new promising modality for treatment of cancer.

 

“We are excited to be partnering our hexokinase II program
with Calithera. We selected Calithera because of their specific expertise and focus in tumor metabolism research and development
and look forward to our continued partnership. This portfolio of hexokinase II inhibitors was discovered using our Translational
Technology® which has also been utilized in the discovery of our other clinical and preclinical programs,” said Stephen
L. Holcombe, President and CFO, TransTech Pharma, LLC.

 

About TransTech Pharma, LLC

 

TransTech Pharma, LLC is a privately held, clinical-stage pharmaceutical
company focused on the discovery and development of human therapeutics to fill unmet medical needs. The Company’s high-throughput
drug discovery platform, Translational Technology®, translates the functional modulation of human proteins into safe and effective
medicines. TransTech Pharma, LLC has a pipeline of small-molecule clinical and pre-clinical drug candidates for the treatment of
a wide range of human diseases, including Alzheimer’s disease, diabetes and other metabolic disorders, inflammation and oncology.
For further company information, visit http://www.ttpharma.com

 

About Calithera Biosciences, Inc.

 

Calithera Biosciences, Inc. (NASDAQ:CALA) is a clinical-stage
pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, an orally bioavailable inhibitor
of glutaminase, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is
headquartered in South San Francisco. For more information about Calithera, please visit www.calithera.com.

 

Contact:

 

TransTech Pharma, LLC

Nura Strong

336-841-0300 ext 164

nstrong@ttpharma.com

 

 

    	70

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]